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University of Pittsburgh, 2007
Sepsis, the tenth-leading cause of death in the United States, accounts for more than $16.7
billion in annual health care spending. A significant factor in these costs are unnecessar-
ily long hospital lengths of stay, which stem from the lack of optimal hospital discharge
policies and the inability to assess a patient’s true underlying health state effectively. Re-
searchers have explored ways of standardizing hospital discharge policies by comparing vari-
ous strategies, but have not been able to determine optimal policies due to the large number
of treatment options.
Furthering the state of research into decisions made in the management of patients
with sepsis, this dissertation presents clinically based optimization models of pneumonia-
related sepsis that use patient data to model disease progression over time. Formulated
using Markov Decision Process (MDP) and Partially Observable Markov Decision Process
(POMDP) techniques, these models consider the clinician’s decisions of when to test for
additional information about the patient’s underlying health state and when to discharge
the patient from the hospital.
This work utilizes data from the Genetic and Inflammatory Markers for Sepsis (Gen-
IMS) study, a large multi-center clinical trial led by the University of Pittsburgh School of
Medicine. A key aim of the GenIMS trial is to demonstrate that the levels of certain cytokines
are predictors of patient survival. Utilizing these results, the models presented in this dis-
sertation consider the question of when to test for cytokine levels using testing procedures
that may be costly and inaccurate. A significant result of this dissertation demonstrates
iv
that testing should be performed when a clinician is considering the decision to discharge
the patient from the hospital.
This study characterizes optimal testing and hospital discharge policies for multiple prob-
lem instances. In particular, multi-region control-limit policies are demonstrated for specific
patient cohorts defined by age and race. It is shown that these control-limit policies depend
on the patient’s length of stay in the hospital. The effects of testing cost and accuracy on
the optimal testing and discharge policies are also explored. Finally, clinical interpretations
of the optimal policies are provided to demonstrate how these models can be used to inform
clinical practice.
Keywords: Markov decision processes, partially observable Markov decision processes, med-
ical decision making, sepsis.
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1.0 INTRODUCTION
1.1 CURRENT SEPSIS MANAGEMENT OPTIONS
Sepsis results from an overwhelming inflammatory response to infection. Under normal cir-
cumstances, the human body mounts a potent, complex immunologic response when invaded
by a pathogen, ensuring adequate protection against infection. For some patients, however,
a deficient immunologic defense may allow infection to become established. On the other
hand, an excessive or poorly regulated response may actually harm the body [117]. By
overproducing or producing the wrong proportions of inflammatory and anti-inflammatory
molecules (also known as cytokines), the body may negatively impact one or more of its
organ systems, leading to organ dysfunction and possibly death. This serious condition,
sometimes referred to as severe sepsis, septic shock, or septicemia, is the tenth leading cause
of death in the United States, as illustrated in Table 1.1.
Researchers continue to explore ways of reducing patient mortality through improving
treatment efficacy at all stages of the disease, yet current therapy options are still mainly
ad-hoc [53] and highly depend on the severity of the disease [117]. Initially, antibiotics may
be used to treat the underlying infection; however, factors such as polymicrobial infections
and antimicrobial-resistant organisms make prompt diagnosis and treatment of infection
difficult [37]. If the administered antibiotics are ineffective, organ support therapies such as
fluid replacement, mechanical ventilation, and blood transfusions, may be needed to prevent
organ failure.
In addition to support treatments, researchers are investigating means by which to control
the body’s inflammatory response. Despite considerable advances in medicine, researchers
still do not have a complete understanding of sepsis at the molecular level [117]. Though
1
Table 1.1: Leading Causes of Death, 2003 [54]
Rank Cause of Death Number Percent of
Total Deaths
· · · All Causes 2,448,288 100.0
1 Diseases of the Heart 685,089 28.0
2 Malignant neoplasms 556,902 22.7
3 Cerebrovascular diseases 157,689 6.4
4 Chronic lower respiratory diseases 126,382 5.2
5 Accidents (unintentional injuries) 109,277 4.5
6 Diabetes mellitus 74,219 3.0
7 Influenza and pneumonia 65,163 2.7
8 Alzheimer’s disease 63,457 2.6
9 Nephritis, nephrotic syndrome,
and nephrosis 42,453 1.7
10 Septicemia 34,069 1.4
11 Intentional self-harm (suicide) 31,484 1.3
12 Chronic liver disease and cirrhosis 27,503 1.1
13 Essential (primary) hypertension
and hypertensive renal disease 21,940 0.9
14 Parkinson’s disease 17,997 0.7
15 Assault (homicide) 17,732 0.7
· · · All other causes 416, 932 17.0
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many studies using cells and animals have greatly improved knowledge of the pathophysiology
of sepsis, it is still not clear what factors are advantageous or deleterious in the progression
of sepsis within an individual. As a result, experimental medications aimed at controlling
the body’s inflammatory response have had limited success [15, 16, 77, 119].
1.2 GENETIC AND INFLAMMATORY MARKERS FOR SEPSIS
(GENIMS)
In an attempt to learn more about sepsis, research efforts such as the GenIMS trial led by
the Department of Critical Care Medicine at the University of Pittsburgh and funded by
the National Institutes of Health [45], are trying to understand the body’s inflammatory
response at a molecular level. The work presented in this dissertation utilizes data obtained
through the GenIMS study, which is the largest study to date of this kind.
The study of specific patient populations has been suggested as a way to improve the value
of results from clinical trials of novel anti-sepsis strategies [6]. For this reason, the GenIMS
study chose to focus on pneumonia, the leading cause of sepsis [91]. Further restricting
the cohort, the study includes only those patients who are admitted to the hospital with
pneumonia (i.e., community-acquired pneumonia). The main goal of the GenIMS study is to
determine the extent to which specific genetic, inflammatory, and clinical factors influence the
development of infection and progression to sepsis, organ dysfunction and death. This goal is
achieved through three specific aims: (1) to determine whether specific DNA polymorphisms
for key inflammatory molecules are associated with the risk of developing pneumonia and
progressing to severe sepsis, septic shock, organ dysfunction, and death, (2) to investigate
the relationships among specific DNA polymorphisms, inflammatory molecule expression,
and clinical course and outcome in infection and sepsis, and, (3) to develop and evaluate
clinical decision tools that include genetic and inflammatory response information.
The work presented in this dissertation extends Aims (2) and (3) by developing and
solving optimization models that consider decisions made sequentially and dynamically in
the care of sepsis patients. Due to the complexity of the disease and its treatment, this work
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chooses to focus on decisions made in two areas of sepsis management: cytokine testing
and hospital discharge policies. These decisions are key disease management problems that
regularly impact sepsis treatment. In particular, this dissertation investigates the questions
of when to test for patient cytokine levels and how the information can be used to optimally
discharge patients from the hospital.
1.3 PATIENT-SPECIFIC HOSPITAL DISCHARGE POLICIES
All models presented in this dissertation are parameterized via patient-based information
obtained through the GenIMS trial to model the clinician’s decision-making process for the
treatment of patients with severe sepsis. In particular, these models focus on developing
standard decision-making policies that can provide clinical guidelines for patient treatment.
For example, the last decision a clinician makes during sepsis treatment is when to discharge
a patient from the hospital.
Evidence has shown that the discharge decision is rarely made using patient-based stan-
dards [50]. With the annual costs associated with severe sepsis exceeding $16.7 billion in the
United States [7], it is highly desirable to avoid unnecessary days in the hospital. Yet, de-
spite attempts to decrease costs by reducing hospital length of stay [41, 78], concerns about
the morbidity and mortality associated with premature hospital discharge have resulted in
substantial differences in length of stay between and within institutions [21, 42]. These differ-
ences suggest that decisions are made in an ad-hoc fashion, often due to physician intuition
and clinical uncertainty [17, 78].
Recent studies have focused on standardizing discharge procedures to reduce cost without
increasing the risk of patient morbidity and mortality. In an attempt to develop patient-
based discharge policies, these studies have explored modeling techniques that consider the
cost-benefit tradeoff underlying the discharge decision. For example, Clermont et al. [24]
developed a dynamic microsimulation model to predict various outcomes for critically ill
patients, including day of discharge from the intensive care unit (ICU). While this model
can be used as a predictive tool, it does not provide patient-specific optimal discharge policies.
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Similarly, Halm et al.[50] used statistical modeling to measure the time to clinical stability
in patients with community-acquired pneumonia. The authors discuss how their results can
be used to improve the efficiency of in-patient management by providing an evidence-based
estimate for optimal length of stay. These estimates, however, cannot be easily translated
into health-based discharge policies.
This dissertation extends these and other previous modeling efforts by presenting a model
and analysis of the hospital discharge decision using a Markov decision process (MDP)
approach. Historically, MDPs [13, 89] have been applied in areas such as inventory control
[29, 56] and production planning [14], but have recently seen increased application in medicine
[98], including organ transplantation [3] and HIV therapy planning [100]. Within the limits
of its assumptions, MDPs provide optimal decision policies. In addition, MDPs can more
efficiently evaluate a larger number of policy alternatives than other modeling techniques
used in sepsis research to date, such as statistics [62], Markov modeling [91], and simulation
[22, 24].
1.4 USING CYTOKINE INFORMATION TO IMPROVE PATIENT
SURVIVAL
A key aim of the GenIMS investigation is to demonstrate that the levels of certain cytokines
are strongly correlated with patient survival. It has been discovered that in some cases, a
patient may appear to be well, but the patient’s cytokine levels indicate that the patient
has a higher probability of death should the patient be discharged from the hospital than if
the patient were to remain in the hospital receiving standard treatment [63]. Assuming that
cytokines are correlated with patient survival, it is clear that knowing the levels of these
cytokines will change how the clinician makes decisions, for example, when to discharge the
patient from the hospital.
The decision of when to test for cytokine information is not obvious for several reasons.
First, the test may be costly both from an economic standpoint and in terms of the time
spent by the clinician in performing the test and analyzing the results. Given this cost, the
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clinician may not want to order a test in each time period leading to periods of time when no
test results are received. Secondly, the testing procedure may be inaccurate. For example,
the test results may have an associated measurement error. Even when the measured test
results are accurate, there may be an error associated with how the clinician interprets the
results with respect to the patient’s true underlying health state. Each of these situations
creates an environment of partial observability, in that the patient’s underlying true health
state is not known with certainty by the clinician.
This dissertation presents a Partially Observable Markov Decision Process (POMDP)
model [81, 82, 103] to explore how testing decisions influence the hospital discharge decision.
POMDPs extend the modeling framework of the MDP by allowing the current state of the
patient to be partially observable. In this case, the true underlying health state can only be
observed through a testing procedure that may have associated error and cost.
POMDPs have been previously applied to medical decision making questions in the areas
of heart disease treatment [51, 85], efficient dosage policies for medical drug therapy [55],
and breast cancer treatment [57], but this is the first study to utilize patient-based data
from a large scale clinical trial to develop optimal policies that can inform clinical decision
making guidelines.
1.5 GENERAL PROBLEM STATEMENT
The cytokine testing and hospital discharge decisions made in the management of a patient
with sepsis can be described more formally as follows.
A patient is admitted to the hospital. At some point at or after hospital admission,
the patient is suspected of having developed sepsis. Once suspected of having sepsis, the
clinician then treats the patient following some general treatment process or strategy. The
data used in this study consider only those patients that are suspected of having sepsis,
based on a variety of criteria utilized by the GenIMS investigator team. This dissertation
does not consider issues related to the diagnosis of sepsis.
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Treatment decisions are made based upon the patient’s current health state, which is
comprised of completely and partially observable elements. Completely observable elements
of the patient’s health state can be directly observed by the clinician. Partially observable
elements, however, are not directly observable, usually because they can only be obtained
through testing procedures that have associated costs and degrees of accuracy.
It is assumed that at regular intervals during the treatment process, the clinician must
make decisions about patient care. Due to the complexity of the disease and resulting
treatment options, this dissertation considers only a subset of the decisions made during
the treatment process, namely, when to order various tests for more information about the
patient’s underlying health state and when to discharge the patient from the hospital. It is
assumed that all other decisions follow the “standard care” process, although as has already
been discussed, opportunities exist throughout sepsis treatment for the standardization of
treatment policies.
At each decision point the clinician can readily observe various completely observable
elements of the patient’s health state. If tests were ordered previously, the clinician may also
have test results to observe. Based on this information, the clinician then chooses either to
discharge the patient from the hospital or to keep the patient in the hospital for continued
treatment. If the clinician chooses to keep the patient in the hospital, then the clinician can
also choose, for a cost, to order one or more tests to obtain additional information about the
partially observable elements of the patient’s health state. It is assumed that the test results
are received at the beginning of the next time period and are therefore available before the
next decision is made.
The clinician’s goal at each decision point is to maximize the patient’s expected survival
over a finite observation horizon. Since sepsis is an acute, short-term disease, patient death
due to sepsis usually occurs within 90 days of hospital admission. As a result, the models
presented in this dissertation measure the value of a decision policy in terms of a patient’s
90-day expected survival as measured from hospital admission. Sepsis treatment typically
occurs over an even shorter treatment horizon. As observed in the GenIMS study, treatment
rarely last longer than 30 days; therefore, the models considered in this dissertation utilize
a treatment horizon of 30 days.
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1.6 DISSERTATION AIMS
This dissertation models this general problem as a POMDP. Due to the complexity of analyz-
ing and solving large-scale POMDPs [18, 103], this dissertation then considers two simplified
model variants. For each of these model variants, the model structure and optimal poli-
cies are analyzed and computational experiments are conducted using patient data from the
GenIMS trial. The overall goal of this dissertation is to provide insight into decision making
strategies for the management of patients with sepsis. In addition, the insight gained from
the application of these novel modeling techniques to the field of medical decision making
will further the roles of industrial engineering and operations research in formalizing deci-
sion making strategies in clinical practice. These goals are further described in the following
sections.
1.6.1 Gaining insight into optimal policy structure
In addition to formulating the clinician’s hospital discharge and testing decisions, the dis-
sertation investigates the mathematical structure of these models.
For example, one goal of this dissertation is to characterize non-stationary optimal poli-
cies for the hospital discharge problem. A non-stationary control-limit policy takes the fol-
lowing form: treat the patient in the hospital until the patient’s health improves and reaches
a time-dependent control limit state, then discharge the patient from the hospital. These
types of policies are appealing since they are easy to understand and can be implemented
as part of a general discharge strategy. In addition to defining optimal policies, properties
of the input parameters and other model components are also evaluated.
Another goal of this dissertation is to explore the impact of test cost and accuracy on
testing and discharge decisions. In particular, the effects of increasing test accuracy and
decreasing test costs on the decision of when to test for additional cytokine information will
be used to motivate the need for more accurate and less expensive testing methods.
From a research perspective, these structural properties provide mathematically interest-
ing insights into a new application of the MDP and POMDP modeling methodologies. From
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an application standpoint, the results help to provide structure to a decision making strategy
that is mainly ad-hoc in practice. As will be discussed in later chapters, these results are
particularly interesting in that they suggest that standard policies are possible. Even though
the models are fairly simplistic from a clinician’s viewpoint, they provide a starting point for
future analysis. These policy structures suggest baseline strategies to inform future policy
decisions within the medical decision making community.
1.6.2 Calibrating complex models with actual patient data
This dissertation also uses patient data from the GenIMS trial to solve various problem in-
stances based on a variety of patient characteristics. It will be shown that the optimal policies
for many problem instances are similar to control-limit type policies. For the POMDP in-
stances, the results pertaining to changes in test cost and accuracy are also validated. While
the specific results are not yet at the level that can be directly implemented in practice, they
do validate many of the results that are shown through the structural analysis. A comparison
of results based on varying patient cohorts is also presented.
From a stochastic optimization research perspective, computational experiments demon-
strate the effectiveness of using the MDP and POMDP modeling techniques to determine
optimal policies for clinical decisions made in the treatment of patients with sepsis. From
an application perspective, computational experiments tie the mathematical models back to
the underlying clinical problem by presenting concrete examples of input parameters and
resulting optimal policies. As will be seen for each instance tested, the optimal policy can
be translated into an actual optimal decision that should be made for each possible state
and stage. This information is particularly useful when explaining the model structure and
results to the medical community in general and to the clinicians that actually make these
treatment decisions in practice.
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1.7 DISSERTATION ORGANIZATION
The remainder of this dissertation is organized as follows: Chapter 2 reviews the literature
concerning the current state of medical decision making in general and as related to sepsis
research in particular. Background information on the modeling methodologies used through-
out this dissertation is also provided. Chapter 3 then presents a formulation of the general
model as presented in the problem description. An overview of the model, its variants, and
its relationship to the remainder of the dissertation are discussed. Chapter 4 then presents a
simplified variant of the general model in which the hospital discharge decision is considered
in an MDP model that uses the Sepsis-related Organ Failure Assessment (SOFA) score to
describe the patient’s completely observable health state. Chapter 5 extends this model with
another simplified variant of the general model in which both the hospital discharge decision
and the cytokine testing decision are considered in a POMDP model that uses the value of
a single cytokine to describe the patient’s observable health state. In both Chapters 4 and
5, structural results of the model formulations and computational experiments utilizing the
GenIMS data are presented and discussed. Chapter 5 also discusses heuristic approaches
for combining the results from the MDP and POMDP models to develop more complex
SOFA- and cytokine-based testing and discharge policies. Finally, Chapter 6 discusses the
contributions of this dissertation from both the medical application and the methodological
research perspectives and provides directions for future research.
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2.0 LITERATURE REVIEW
2.1 CURRENT METHODS IN SEPSIS MODELING
Until recently, clinical trials aimed at assessing the efficacy of treatment options for sepsis
have met with limited success due both to trial design [6] and treatment options [20]. By
the year 2000 there were over thirty large randomized controlled trials (RCTs) of novel anti-
sepsis strategies that failed to demonstrate any clinical impact [6]. Since then, numerous
other RCTs have met with the same fate [25, 53]. Due to the complexity of the disease, RCTs
have been unable to adequately compare the virtually limitless management possibilities.
These failures provide strong evidence of the need for advanced modeling techniques that
allow for the evaluation of a large number of treatment decisions made over time without the
need for large RCTs. With the advent of clinical studies like GenIMS, aimed at gathering
data concerning the underlying progression of the disease, the use of mathematical modeling
techniques to analyze and interpret therapeutic options has become increasingly important.
Mathematical modeling serves to extend current research efforts by providing the capability
to analyze both current and new treatment strategies.
Many clinical researchers have begun to develop models to compare available manage-
ment options [33] based on clinical data from large-scale trials like GenIMS. These studies
are aimed at assessing the effectiveness of various anti-sepsis treatments and strategies and
demonstrating a relationship between one or more clinical, biological, inflammatory, and
genetic factors and patient survival. The models presented in this dissertation extend these
efforts by allowing for the implicit comparison of virtually all decision options to determine
the optimal strategy.
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This section both reviews the literature surrounding sepsis modeling as well as presents
the current state of medical decision making methodology including cost-effectiveness analy-
sis, decision trees, influence diagrams, Markov modeling, Bayesian analysis, simulation anal-
ysis, and Monte Carlo simulation. Relevant studies involving other medical decision making
questions are discussed as needed to describe the application of a specific methodology. Most
importantly, the motivation for the modeling techniques used in this dissertation, namely
Markov decision processes and partially observable Markov decision processes, is presented.
Since the models presented in this dissertation are the first applications of these techniques
to questions in sepsis management, applications of these methods to other areas in medical
decision making are also reviewed.
2.1.1 Cost-effectiveness analysis
Cost-effectiveness analysis (CEA) [48, 86] is a commonly used analysis technique that in-
volves the calculation and comparison of the costs and effects of various disease management
options. The relative cost-effectiveness of each option can then be assessed by calculating
and comparing their respective incremental cost-effectiveness ratios. In the area of sepsis
research, Wang et al. [115] conducted a cost-effectiveness analysis to compare the use of var-
ious treatments in the management of sepsis. The authors concluded that the epidemiology
of the disease state is an important factor in cost-effectiveness analysis and recommended an
infection-specific approach to modeling treatment options in sepsis. Burchardi and Schnei-
der [16] compared intensive care unit (ICU) care versus non-ICU care for the treatment of
patients with sepsis. They also investigated the cost-effectiveness of potential new therapies
and concluded that new therapies should be directed at patients that are the most likely to
benefit from the costly intervention. Both of these studies demonstrate the ability of cost-
effectiveness analysis to compare known treatment strategies and possibly suggest direction
for new research. However these studies cannot be used to suggest what these new strategies
should be.
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2.1.2 Decision trees and influence diagrams
To evaluate the effects of a particular disease management strategy, medical decision makers
often employ graphical analysis techniques such as decision trees [86] and influence diagrams
[33]. Decision trees use a logical, cause-and-effect framework to depict possible decision
choices and all possible outcomes for each choice. The outcomes can be deterministic or
based upon a known probability distribution. Marchetti et al. [76] used a decision tree
framework to demonstrate that a combined prophylactic splenectomy and cholecystectomy
provides a substantial gain in quality-adjusted life expectancy in certain patient cohorts
as compared to the no surgery option in the treatment of patients with mild hereditary
spherocytosis.
Unfortunately, as the number of possible decisions increases, the decision framework can
become unmanageable and difficult to analyze. This problem occurs, in particular, when a
decision or series of decisions must be made sequentially throughout time with the effects
of earlier decisions influencing later decisions. The MDP framework discussed in the next
section will improve this framework, even though it too suffers from what has become known
as the “curse of dimensionality” [12], though at a much later stage than the decision tree.
While a decision tree describes the causes and effects of decisions made in a specific
management strategy, an influence diagram is a network with directed arcs and no cycles
that is used to show relationships between random variables and possible decisions. Unlike
in a decision tree, where the probability distributions that characterize the effects of making
a particular decision are necessary to evaluate a decision policy, the influence diagram can
actually be used to gain insight into the value of the transition probabilities themselves. This
technique, however, requires an in-depth understanding of the relationships between variables
that comprise the system under analysis. In the field of sepsis treatment, researchers are
still working to develop a fundamental understanding of the disease [53]. A specific aim of
the GenIMS study is to “investigate the relationships among specific DNA polymorphisms,
inflammatory molecule expression, and clinical course and outcome in infection and sepsis.”
This information will be useful in constructing an influence diagram of sepsis as part of
future research efforts.
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As the relationships between patient health states become more complicated, influence
diagrams will often employ Bayesian methods to capture conditional probability distribu-
tions between random variables. Spiegerlhalter presented graphical Bayesian methods that
are basically complex influence diagrams [108]. Computational methods were also discussed.
Computational methods for using influence diagrams as input to more advanced modeling
techniques also exist [73, 99]. In particular, Magni and Bellazzi [73] developed a software
package called DT-Planner that used an “influence view” to depict the probabilistic rela-
tionships between variables that is then used to specify an MDP formulation of the model.
2.1.3 Markov modeling
Extending the capabilities of decision trees and influence diagrams, a common structure used
to calculate the effects of a particular disease management option is the Markov model [83,
107]. Markov modeling is a decision-analytic technique in which all of the relevant conditions
in a particular problem are represented as a set of states that are mutually exclusive and
exhaustive. Patients (or portions of an entire cohort of patients) move through the model
according to probabilities that govern how likely it is to transition from one state to another.
The long-term behavior of the model provides insight into the expected behavior of the
patient or group of patients under the current system as modeled. For more information on
the general application of Markov models to medical decision making, the reader is referred
to Sonnenberg and Beck [107].
Markov modeling has been used to understand the progression of sepsis in patients.
Rangel-Frausto et al. [92] conducted a nine-month prospective cohort study, using their
results to develop a Markov model of the natural history of sepsis. This model has the ability
to predict the probability of movement to and from varying stages of sepsis (sepsis, severe
sepsis, and septic shock) and can be used to predict the reduction in end-organ dysfunction
and mortality resulting from the use of increasingly effective antisepsis agents. Bauerle et al.
[11] developed a three-state (well, septic, and dead) Markov model to describe the course of
the disease in critically ill patients. They used this model to develop risk profiles of various
patient groups, allowing for the comparison between age- and gender-specific survival rates.
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In addition to the study of sepsis, Markov modeling has been used in other areas of med-
ical decision making, such as the study of patient preferences for various treatment options.
For example, Ahn and Hornberger [1] developed a Markov model to asses organ quality from
the patient’s perspective in the allocation of organs for transplant to patients with End-Stage
Renal Disease (ESRD). In their paper, Ahn and Hornberger presented a decision model that
considers patient preferences for specified health states that then influence the patients’ de-
cisions about which organ are acceptable for transplantation. The authors demonstrated
that patients with favorable health characteristics can afford to be more selective about the
quality of the transplant organ whereas less healthy patients may be inclined to select a
lower-quality organ. In another interesting application of Markov modeling, Kao [60] pre-
sented a semi-Markov process model that looks at patient paths through the hospital based
on various arrival rates to determine care requirements based on patient characteristics. The
semi-Markov nature refers to the incorporate of time into the state description, since patient
length of stay in the hospital was seen to be a significant factor in care requirements.
2.1.4 Simulation
In recent years, simulation has become a popular and commonly used modeling method in
medical decision making. Simulation analysis [68] is a method by which logical rules are used
to replicate, or imitate, a system in order to gain understanding and insight into how that
system behaves. For example, Clermont et al. [24] developed a dynamic microsimulation
model to predict various outcomes for critically ill patients, including day of discharge from
the intensive care unit (ICU). While this model can be used as a predictive tool, it does
not provide patient-specific optimal discharge policies. Similarly, Saka et al. [96] developed
a simulation model of sepsis in order to study the rates of hospital discharge and patient
death based on the patient’s changing health state over time as well as static variables such
as age and race. The authors calibrated the model with clinical data from the GenIMS
trial. As will be discussed in future chapters, the work presented in this dissertation extends
this simulation model by modeling the clinician’s decision making process and how it affects
the patient’s health state transitions. Other simulation models in the medical literature
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can be found in the areas of critical care medicine [67], HIV modeling [102, 104], organ
transplantation [66, 96, 101], and infectious disease modeling [70].
Monte Carlo simulation [68] is a specific simulation tool that considers a static framework,
or a system in which the passing of time does not need to be explicitly modeled. Similar
to Markov modeling, the model consists of possible states with transition probabilities that
govern how patient transitions between these states. In a Monte Carlo simulation, however,
patients are sent through the model one at a time and random numbers are used at each
transition point to determine how the patient transitions through the model. Studying
the results for large cohorts of patients lends insight into the functioning of the system. For
example, Su et al. [111] developed a Monte Carlo simulation model to compare various organ
allocation policies for kidney transplantation to study the effects of incorporating patient
preferences into the allocation policy. Related works by these authors include [120, 121].
Cost-effectiveness analysis, decision trees, Markov modeling, and simulation are effective
methods of evaluating and comparing specific management options, but they cannot be
used to compute an optimal management strategy comprised of dynamic decisions made
throughout time. Even using these methods to evaluate a large number of management
options can become computationally prohibitive.
2.1.5 Motivation for advanced techniques
This dissertation extends current research efforts in the study of sepsis treatment by utilizing
an modeling technique called the Markov decision process (MDP) to consider not only the
stochastic progression of the disease, but the resulting effects of sequential decisions made
throughout time as well. MDPs extend the framework of the Markov process model by
introducing a control process that directly influences how a patient transitions between
states. The solution to an MDP is an optimal decision making policy that can be used to
inform clinical practice, not merely an evaluation of a few pre-defined policies. Section 2.2
describes the MDP modeling structure in more detail.
This dissertation presents the first MDP model to consider decisions made in the treat-
ment of sepsis. MDPs, however, have been successfully applied to medical decision making
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questions in the areas of organ transplantation [3, 4, 26], hereditary spherocytosis treat-
ment [74], and the control of infectious disease epidemics [69]. A general review of MDPs in
medicine is provided in [98].
Alagoz et al. [3] presented an MDP model that addresses the clinical question of when
to conduct a living donor liver transplant in order to maximize the patient’s life expectancy
(or quality-adjusted life expectancy). The authors presented clinically intuitive conditions
on the input parameters that ensure that the optimal policy will be of a particular type.
Computational results using patient-based data were included to support these policies for
specific patient cohorts. In [4], Alagoz et al. extended their earlier work by modeling
the patient’s choice between a living donor transplant and a cadaveric liver transplant in
addition to the clinician’s decision of when to conduct the transplant procedure. Structural
results demonstrated specific policy types, which were confirmed through computational
experiments using clinical data. Another liver transplant study by these authors is [2].
David and Yechiali [26] used an MDP to model the decision of whether to accept or
reject a kidney transplant offer. The authors considered how the length of the patient’s time
under medical care affects the optimal policy. Various organ offer rates were tested and a
numerical example using clinical data was interpreted in the context of the model.
Magni et al. [74] demonstrated the improvements that the MDP offers over traditional
modeling approaches such as decision trees and influence diagrams, mainly in its ability to
consider dynamic, sequential decisions. They presented an MDP model of when to perform
prophylactic surgery in patients with mild hereditary spherocytosis. Using data from the
literature and clinical expertise, the authors modeled the dynamic progression of the disease
and used this understanding of the disease to solve both their MDP model as well as a
traditional static model. Comparing model results, they were able to demonstrate significant
gains in patient quality-adjusted life days by delaying surgery in some cases according to the
MDP optimal policy versus the static policy.
Lefevre [69] modeled the spread of an infectious disease in a closed population. The
continuous-time Markov decision process considered decisions such as quarantining section
of the population and implementing medical care programs to control the spread of the
disease. In addition to presenting the model formulation, Lefevre analyzed the dependence of
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the optimal policy on the input parameters and provided conditions on the input parameters
that ensure that the optimal quarantine and medical program levels do not increase as the
size of the infected population increases.
Markov decision problems are based upon the assumption that the current state is com-
pletely observable, i.e., all information about the state can be observed or known with
complete certainty. The partially observable Markov decision process (POMDP) [13, 82], a
generalization of the MDP, relaxes this assumption and allows the model to consider patient
health states that can only be observed through an inspection or testing procedure. This
state, therefore, is said to be partially observable because the observation procedure is either
inaccurate (due to testing and/or test interpretation error) or costly (and therefore it may
not be performed at every decision point). The POMDP framework, described in detail
in Section 2.3, describes the patient health state not by the values of the patient variables
themselves; rather, the state is described as the clinician’s belief in what the variables are,
which is based upon the values of the observations received up until the current point. While
this framework is much more general than the MDP, its data requirements make it difficult
to obtain practical results.
This dissertation is the first work to utilize POMDPs in the study of sepsis management.
It is also one of the first studies to use patient-based data to derive optimal decision policies
in the hopes of informing clinical practice. POMDPs have been previously applied in other
areas of medical decision making, such as ischemic heart disease treatment [51], congenital
heart disease treatment [85], efficient dosage policies for medical drug therapy [55], and
breast cancer treatment [57].
Hauskrecht and Fraser [51] presented a POMDP model for the management of patients
with ischemic heart disease. The authors constructed a hierarchical Bayesian belief network
based on data from the literature and clinical expertise to represent the disease dynamics.
Their work demonstrated the ability of the modeling framework to provide clinical insight,
but they discussed issues with increasing computational complexity as the model size in-
creases.
As in [51], Peek [85] presented an influence diagram to describe the underlying relation-
ships between state variables in patients with ventricular septum defect, a disorder with
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characteristics for congenital heart disease. The author utilized this diagram to construct a
POMDP model that considers the various treatment decisions such as when to perform a
chest X-ray and when to perform surgery. While the model captured many aspects of the
disease and its treatment, the author does not present structural policy results or solutions
obtained from clinical data.
Hu et al. [55] presented a POMDP model to determine efficient dosage policies from
medical drug therapy. Specifically, they considered the effects of various information gath-
ering policies, such as myopic policies and active learning policies. Computational results
were presented to compare policy types and a passive information gathering strategy was
suggested for use in clinical practice.
The work presented in this dissertation investigates questions in sepsis management using
both MDPs and POMDPs. In addition to presenting the model formulation, the models are
solved using patient-based data obtain from the GenIMS trial. Model results are interpreted
and general policy recommendations are presented to inform clinical practice. The main
contribution of this work is its ability to provide insight based on an analysis of model
structure and results calculated from patient-based data.
Unfortunately, while the models discussed in this review have made great strides in
presenting and motivating the use of these frameworks and in demonstrating the complex-
ity they can incorporate, the models have not led to implementable results, largely due
to insufficient data availability. As additional data become available, many of the models
and techniques in the literature will prove to be increasingly valuable to clinical practice.
To begin to bridge the gap between theory and practice, the model presented in this dis-
sertation attempts to incorporate sufficient complexity to capture the dynamic nature of
disease progression, while still allowing for solutions to be obtained with available data. The
next sections provide background information on the mathematical structure of MDPs and
POMDPs before moving on to present the general model.
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2.2 MARKOV DECISION PROCESSES
The Markov decision process [12, 13, 89] is a general modeling technique used to formulate
a problem involving sequential decisions made over time. The objective is to maximize a
reward function that quantifies the effects of all possible outcomes of these decisions. A
basic MDP model has two main features: a discrete-time dynamic and stochastic system
that underlies the entire problem and a reward function that is additive over time.
The underlying dynamic system describes how the system changes as decisions are made
at discrete points in time called stages. At each stage, the decision maker observes the state
of the system and chooses one action from the set of all actions available at that specific
point in time. Based on the state and action chosen, the decision maker receives some reward
and then the system’s state changes based on specified transition probabilities. A policy is a
decision rule that tells the decision maker which action to take when a patient is in a given
state at a given time. The value of this decision rule is calculated through the value function.
The optimal policy is the policy that maximizes the total expected reward received by the
decision maker; or, in other words, the policy that maximizes the value function for each
starting state.
A basic assumption of the Markov decision process is that the state is Markovian. In
other words, the current state in the model is assumed to capture all information necessary to
make a decision moving forward. While this assumption may seem unreasonable, the state
description can be altered to incorporate any historical information that may be needed
when making a decision in the current stage. Unfortunately, data requirements necessary
for the solution of the model increase exponentially with the size of the state space, which
is often referred to as the “curse of dimensionality” [12]. These issues will be discussed in
more detail as they related to the models presented in later chapters.
The definition of stages allows for the separation of the class of MDPs into finite- and
infinite-horizon problems. In finite-horizon problems, rewards are received over a finite num-
ber of stages while infinite-horizon problems allow for the accumulation of rewards over an
uncertain or indefinite horizon. The models presented throughout this dissertation are finite-
horizon problems, though finite-horizon problems can be reformulated as infinite-horizon
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problems through a standard augmentation of the state with the stage [32]. A general
description of a finite-horizon problem is provided.
Following a modified version of the notation from Puterman [89], let N be the time-
horizon and let S be the defined state space of the MDP. For every stage t and state st ∈ S,
let the set of feasible decisions or actions be A(st), where for every action at ∈ A(st), the
decision maker receives reward rt(st, at). It is assumed that the rewards are bounded and
that S and A(st) are discrete and finite. A transition from state st to state st+1 when action
at ∈ A(st) is chosen occurs with probability pt(st+1|st, at).
Let a policy d = {d1, d2, . . . , dN} be a sequence of decision rules, where a decision rule dt
is a function mapping states into actions at stage t such that dt(st) ∈ A(st). The application
of such a policy induces a Markov chain where Xt is the state of the system at stage t and
Yt is the action chosen in state Xt, so that Yt = dt(Xt).
The objective of an MDP is to find an optimal policy d∗ that maximizes one of three
criteria: the total expected reward, the total discounted expected reward, or the average
reward per stage. The total expected reward criterion is often used when the reward received
in later stages of the model has the same value as those received in earlier stages, which is
often the case for finite-horizon problems with a short time horizon. This criterion is used in
the models presented in this dissertation as the time horizon is relatively short as compared
to the lifetime of the patient.
In infinite-horizon problems, particularly those that consider decisions that may take
place very far in the future, the total discounted expected reward criterion is used to give
more importance to decisions made in the near future than those made at a later point in
time. For more information on the total discounted expected reward criterion, the reader is
referred to [13, 95]. Studies, such as [38], have also explored the effects of various weighting
mechanisms for discrete time, infinite horizon MDPs.
For infinite-horizon applications where discounting is inappropriate and there is no nat-
urally occurring cost-free state the system eventually enters, then the total expected reward
criterion may not be applicable because the total cost is not guaranteed to be finite. In such
cases, it is often advisable to use the average reward per stage criterion [13].
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The total expected reward criterion is further explained as it will be used in the models
presented throughout this dissertation. Let V dt (st) represent the total expected reward when
policy d is used and the system starts in state st where,
V dt (st) =
N∑
t=1
rt(Xt, Yt).
Under the assumptions of bounded rewards and finite S and A(st), V
d
t (st) exists for each
d ∈ DMD, the set of all deterministic, Markovian policies [89]. Let V ∗t (st) denote the optimal
total expected reward for each state st ∈ S where,
V ∗t (st) = max
d
V dt (st).
Then, by the principle of optimality [89], V ∗t (st) can be found by solving the standard set of
optimality equations, also known as the Bellman equations [12]:
V ∗t (st) = max
at∈A(st)
rt(st, at) + ∑
st+1∈S
pt(st+1|st, at)V ∗t (st+1)
 , for t = 1, . . . , N − 1, and
V ∗t (sN) = rN(sN), for all sN ∈ S.
2.2.1 MDP structural results from the literature
Each proposed model in this dissertation is formulated as an optimal stopping problem with
ordered states. Optimal stopping problems are discussed in greater detail in Section 2.4. In
this problem, the decision maker can either decide to continue or to stop the process based
on the current state of the system. A general description of the optimal stopping problem
with a completely observable state space can be found in [31, 34].
Assuming an ordering on the state space, the most significant result for an optimal
stopping problem is to demonstrate that the optimal policy is of control limit type. Using
the notation introduced at the beginning of Section 2.2, a control limit policy [89] is composed
of decision rules, dt(st), of the form:
dt(st) =
 a1 st < s
∗
t
a2 st ≥ s∗t .
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This equation says that if the value of the state at time t is less than some value s∗t , which
may or may not be time-dependent, then the optimal action is a1. Otherwise, the optimal
action is a2. Bertsekas [13] shows several optimal stopping problem applications (e.g. asset
selling, purchasing with a deadline) for which the optimal policy is of control limit type.
Puterman [89] presents general conditions for the existence of a control limit policy,
which include:
1. Inductively showing that the optimal value functions from t onward are nonincreasing or
nondecreasing in the state, and
2. then showing that the value function itself is superadditive or subadditive.
These conditions are further discussed in Chapter 4 as they relate to the models presented
in this dissertation. Examples of control limit policies can be found in [13, 89]. In addition to
satisfying these general conditions, application-specific conditions have been demonstrated
in the literature. For example, Alagoz et al. [3] provide clinically realistic conditions under
which it is optimal to perform a living donor liver transplant.
2.2.2 MDP solution procedures
The separability of the MDP decisions allows for the decomposition of the above problem
into smaller related subproblems. As a result, such decisions can be solved using a simple
backward induction algorithm [89], which is presented in Appendix C. Backward induction
is used to solve the MDP models presented in this dissertation. A variety of techniques exist
for solving infinite-horizon problems, including value iteration, policy iteration, or modified
policy iteration [13, 89].
An MDP can also be converted to an equivalent linear program and solved using standard
linear programming techniques [28, 32, 75]. This solution method also has advantages from a
modeling perspective in that it allows for the incorporation of constraints [5, 52]. Simulation
can be used to determine suboptimal decision policies, particularly for the case of Semi-
Markov models in which the underlying stochastic process cannot be characterized by the
Markov chain alone [49].
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The Markov decision process extends commonly used methodologies such as Markov
modeling and simulation in that it can be used to compute optimal policies rather the
merely evaluate a prespecified policy. One potential disadvantage of the MDP is that it
assumes that the state of the system is completely observable at each decision point. In
many applications in medicine, this is often not the case as the clinician observed available
information and then tries to determine the patient’s true underlying health state from this
observed information. Partially observed Markov decision processes, as discussed in the next
section, incorporate a partially observable state space and an observation process to more
accurately model these types of situations.
2.3 PARTIALLY OBSERVABLE MARKOV DECISION PROCESSES
The POMDP generalizes the MDP structure in that the patient’s state is no longer required
to be fully observable. As a result, the basic POMDP model includes an observation process
in addition to the discrete-time dynamic and stochastic system and additive reward function
that comprise a standard MDP. This observation process relates information that can be
readily observed by the decision maker to the true system state through a known probability
distribution.
The structure of a POMDP includes the five basic components of an MDP: stages, states
(also referred to as core states), actions, transition probabilities, and rewards. In addition,
a POMDP includes observed states (or information states), which describe the information
about a patient that a clinician can directly observe (such as test results); a belief vector,
which describes the probability that a patient is in a given core state given the patient’s
current observed state; and observation probabilities, which relate the observation states to
the core states. The observation probabilities in the context of the models presented in this
dissertation can also be described as test error (or test interpretation error).
Recalling the notation from the previous section, N represents the time-horizon and S
represents the defined core state space of the POMDP. A key difference between the MDP
and the POMDP is that the core state st cannot be directly observed by the decision maker.
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Define O as the set of observed states. The probability of observing state ot+1 ∈ O given that
the underlying core state is st, zt(ot+1|st, at), depends both on the probabilistic relationship
between ot+1 and st, called the observation probability, as well as the action chosen. Since
the observation process may have an associated cost or error, the decision maker may not
choose to make an observation in every stage. As a result, let pit(st) denote the decision-
maker’s belief that the patient is in core state st at stage t. Let pit denote the belief vector
that defines the probability distribution over all st ∈ S, where Π defines the set of all possible
belief vectors.
Using an initial estimate of the probability distribution over the true core states (called
the prior distribution), the current observation of the patient, knowledge of the last action
taken, and a distribution for the observation error (test error) if an observation (test result)
was just received, Bayesian updating is used to form new estimates of the core states (called
the posterior distribution). In other words, the following updating function is used to update
pit(st) to pit+1(st+1):
U(pit+1(st+1)|ot+1, at, pit(st)) ≡ pit+1(st+1)
=
z(ot+1|st+1, at)∑st∈S pt(st+1|st, at)pit(st)∑
st+1∈O z(ot+1|st+1, at)
∑
st∈S pt(st+1|st, at)pit(st)
.
It has been established that pit summarizes all of the information necessary for making a
decision as stage t [13, 106]. For every stage t and belief vector pit ∈ Π, let the set of feasible
decisions or actions be A(pit). Note that the MDP in which the core state was completely
observable was defined on a finite state space. Since the core process must now be observed
through an observation process, the POMDP can be defined as an equivalent MDP on an
uncountable state space defined by the set of all possible belief vectors.
For notational convenience, define the probability of receiving observation ot+1 at time
t+ 1 given that the belief vector was pit at time t as γt(ot+1|pit, at), where
γt(ot+1|pit(st), at) =
∑
st+1∈O
z(ot+1|st+1, at)
∑
st∈S
pt(st+1|st, at)pit(st).
For every action at ∈ A(pit) define a reward function rt(st, at) that describes the imme-
diate reward received when action at is taken at time t when the system is in core state
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st. The resulting reward function rt(pit(st), at) can then be calculated as rt(pit(st), at) =∑
st∈S rt(st, at)pit(st).
As in the MDP, let a policy d = {d1, d2, . . . , dN} be a sequence of decision rules, where a
decision rule dt is a function mapping states into actions at stage t such that dt(pit) ∈ A(pit).
The application of such a policy induces a Markov chain where Xt is the state of the system
at stage t and Yt is the action chosen in state Xt, so that Yt = dt(Xt).
Let V dt (pit) represent the total expected reward when policy d is used and the system
starts in belief state pit where, V
d
t (pit) =
∑N
t=1 rt(Xt, Yt). Let V
∗
t (pit) denote the optimal total
expected reward for each state pit ∈ Π where,
V ∗t (pit) = max
d
V dt (pit) for all pit ∈ Π.
As shown in [82, 103], V ∗t (pit) satisfies the following recursion:
V ∗N(piN) = rN(piN),
V ∗t (pit) = max
{
rt(pit, at) +
∑
ot+1∈O γt(ot+1|pit(st), at)V ∗t+1[U(pit+1|ot+1, at, pit(st))].
}
for all pit ∈ [0, 1].
POMDP models present a great challenge as they are in general more difficult to analyze
than their MDP counterparts and their data requirements are significantly greater. The
optimal policies of the more general models typically lack structure and the added uncer-
tainty in the problem due to the incorporation of partial observability results in additional
computational difficulties.
2.3.1 POMDP structural results from the literature
Monahan [81] considers partial observations and presents a general model of the optimal
stopping problem where complete information can be purchased by testing. Unlike the
completely observable optimal stopping problem referred to in Section 2.2.1, Monahan is
able to demonstrate through an example that the optimal policy for this case may not have
special structure. In particular, he shows that control-limit policies may not exist, the set
of states for which it is optimal to purchase information (test) may not be convex, and
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the optimal policies may not be monotone. In previous work, Monahan [79, 80] shows the
optimal policy to be well structured for specific cases of the finite horizon partially observable
stopping problem such as under conditions of perfect observability and complete uncertainty.
Monahan [82] explores the effects of partial observability on the optimal solution. Chap-
ter 5 expands his results by exploring the effects of test cost and accuracy on the optimal
decisions of when to test for cytokine levels and when to discharge the patient from the
hospital.
In a more general paper, Smallwood and Sondik [103] show that for any finite-horizon
POMDP, the optimal value function, Vn(pi), is piecewise linear and convex. Define N as the
total number of decision periods and n as the number of decision periods remaining. Let pii
be the probability that the current internal state of the system is i, where the belief vector
is pi = [pi1, . . . , piN ].
Theorem 2.3.1 (Smallwood and Sondik (1973)) Vn(pi) is piecewise-linear and convex, and
can thus be written as
Vn(pi) = max
k
[
N∑
i=1
αki (n)pii
]
for some set of vectors αk(n) = [α
k(n)
1 , . . . , α
k(n)
N ], k = 1, 2, . . ..
This result demonstrates that the state space can be partitioned into a finite number of
convex regions within which the value function is linear. Smallwood and Sondik use this
partitioning in an algorithm for solving finite-horizon POMDPs as will be discussed in the
following section.
2.3.2 POMDP solution procedures
POMDPs are in general more difficult to analyze than their MDP counterparts. The standard
approach to solving POMDPs involves transforming the POMDP into an equivalent, fully
observable MDP, over all possible probability distributions on the original core state space
[9, 105]. The continuous state space of the resulting MDP is computationally difficult to
handle, resulting in limited and complicated solution algorithms [72].
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Feasible numerical methods often involve reducing the infinite number of possible states
of the system to a finite grid of points [71]. As stated previously, Smallwood and Sondik [103]
show that for a finite-horizon problem, the optimal value function is piecewise linear and
convex. Thus, the state space can be partitioned into a finite number of convex regions within
each of which the value function is linear. Unfortunately, these regions must be reconstructed
at each iteration of their proposed algorithm. Not only is the additional computational effort
significant, but the number of regions necessary for an exact solution can grow exponentially
with time.
Sondik’s One-Pass algorithm [103] is the basis for the majority of the algorithms in the
artificial intelligence literature to-date. The algorithm proceeds from an arbitrary belief
point, constructs a set of vectors that describe the optimal value function based on that
point, and then determines the set of constraints over the belief space where that vector is
guaranteed to be dominant. Linear programming is then used to define points for the next
iteration of the algorithm as it proceeds to calculate the value function for the next stage.
The number of vectors generated to describe the value function from one stage to the next
can become prohibitively large as the state space and time horizon increase. In addition, the
data structures used to store the vector information can be cumbersome.
More recent algorithms have explored dominance criteria and pruning mechanisms to
reduce the number of vectors needed to completely describe the value function. Examples
include Cheng’s Linear Support algorithm [18] and Littman et al.’s Witness algorithm [18].
For an in-depth review of these and other POMDP solution procedures, the reader is re-
ferred to Cassandra [18]. While the artificial intelligence community continues to research
efficient algorithmic procedures, current algorithms require an in-depth understanding of
data structures and computer programming for successful implementation.
The overwhelming computational burden associated with solving POMDPs demonstrated
Sondik’s One-Pass algorithm and more recent algorithms [106, 118] precludes their appli-
cation to problems of practical size [84]. As a result, many heuristics and approximation
methods for solving POMDPs have been proposed [18, 72]. For example, Lovejoy [71] pro-
poses an approximation method that applies a bounding procedure to the Smallwood and
Sondik algorithm, allowing for the solution of larger problems. Platzman [88] proposes an
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approximation method where decisions are made based on a finite memory of the most re-
cent decisions and observations. Yet, he notes that this memory can grow prohibitively
large before the approximation is acceptable. Kakalik [59] and Eckles [35] discuss using an
approximate value function based upon linear interpolation between fixed, discrete points in
the continuous state space, but do not present results. Sondik [105] later provides bounds
for Eckles’ method.
A full-scale implementation and comparison of existing complex algorithmic methods is
outside the scope of this dissertation. Rather, a heuristic approach is proposed and used
to solve the POMDP model presented in Chapter 5. This heuristic takes advantage of the
fact that the POMDP models presented in this dissertation are formulated as MDPs with
a continuous state space. The heuristic first discretizes the belief vector and then incorpo-
rates the updating function into the standard backward induction algorithm as described in
Appendix C. One area for future research would be to further explore existing exact and ap-
proximate solution procedures in conjunction with researchers from the artificial intelligence
community, utilizing the available GenIMS data.
2.4 OPTIMAL STOPPING PROBLEMS
Both the MDPs and the POMDPs described in this dissertation can be formulated as optimal
stopping problems [31]. In an optimal stopping problem, a decision maker views rewards
sequentially at discrete points in time. In the MDP, the decision maker can either accept
the reward (i.e., choose to discharge the patient and “receive” the patient’s current expected
survival) or reject the reward (i.e., keep the patient in the hospital for one more time period).
In the POMDP, before accepting or rejecting the current reward, the decision maker may
purchase information regarding its true value. Once the gathering of information regarding
the current reward has ended, the decision maker must either decide to accept the current
expected reward, thus ending the decision process, or to reject the current expected reward,
pay a fixed continuation cost (which in the models presented in this dissertation could
represent the additional day of survival in the hospital as well as the costs of care, the
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risk of nosocomial infection, or even the patient’s quality of life), and then imperfectly view
the expected reward in the next time period. In either the MDP or the POMDP case, the
decision makers face the same problem at each decision point. The objective of the optimal
stopping problem is to determine a decision rule that indicates which action to take (continue
or stop), based on the information available at each decision point to maximize the total
expected reward.
A classic optimal stopping problem is the secretary problem [43, 44]. In its simplest form,
the secretary problem has the following features [44]. There is a single secretarial position
available and the total number of applicants for this position, n, is known. The applicants
are interviewed sequentially in a random order. These applicants can be ranked in order
from best to worst, without ties, but the decision to accept or reject the current candidate
can only be made based on the relative ranks of the candidates viewed so far.
The decision maker wants to choose the very best applicant for the position, but once an
applicant is rejected, she cannot later be accepted. It has been shown that the optimal policy
for this case is of the following form. For large n, it is optimal to wait until approximately
37% of the applicants have been interviewed and then to select the next relatively best
candidate [44, 46]. Therefore, if the best candidate was in the first 37%, then the optimal
solution will be to choose the nth candidate.
There are many applications of this problem. It was first proposed by Cayley [19] in the
context of determining an optimal policy for playing the lottery. Other applications include
hypothesis testing [8, 113, 114], asset selling [13, 61, 89], and purchasing call options [89].
Considering the decision problem of when to discharge a patient from the hospital can also
be considered in the context of the secretary problem. In this case, there are a fixed number
of days on which the patient can be released from the hospital. Associated with each of
these days is a stochastic reward. The decision maker sequentially views these rewards and
must choose to accept them (discharge the patient) or reject them (keep the patient in the
hospital). Once the decision maker rejects a reward, the decision maker cannot later accept
it (i.e., the decision maker cannot go back and release a patient on a previous day).
Extensions of the simple secretary problem include considering correlations between the
ranks of sequential candidates [13], retaining the option to accept past candidates [13, 39],
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and the incorporation of partial information [79, 80, 81, 87, 97, 109, 110]. This last case is
of particular interest as the clinician’s problem can also be formulated as a POMDP.
Of the literature reviewed, the most relevant case is that presented by Monahan [81]
who considers partial observations and presents a general model of the optimal stopping
problem where complete information can be purchased by testing. His model assumes that
the time required to perform the test procedure is instantaneous and that multiple tests can
be performed before making a decision at any decision point. The POMDP models presented
in this dissertation consider not only which tests to order, but when they should be ordered.
Unlike in the completely observable optimal stopping problem, Monahan is able to
demonstrate through an example that the optimal policy for this case may not have special
structure: control-limit policies may not exist, the set of states at which it is optimal to
purchase information may not be convex, and the optimal policies may not be monotone.
However, Monahan has also shown the optimal policy to be well structured for specific cases
of the partially observable stopping problem, such as under conditions of perfect observability
and complete uncertainty [79, 80].
2.5 MACHINE MAINTENANCE AND REPLACEMENT PROBLEMS
The POMDP models formulated to address the management of severe sepsis have some
similarities to problems found in the machine maintenance literature; however, the differences
between the problem structures are also readily apparent.
The general form of the machine maintenance problem can be described as follows [36,
64, 94]. A production process produces items at the beginning of distinct time periods. It is
supposed that at any time point the production process may be in any one of a countable
number of states and that the quality of the item produced is a function of this underlying
state. It is also supposed that the state of the process at any time point is not known and
can only be determined by sampling the item produced. A cost is associated with sampling
the item. This cost may be a function of the current state. The purpose of sampling is not
to replace a poor item with a good one, but rather to check the manufacturing process.
31
At each time point, the decision maker selects an action from the set of possible actions
including: replacement, repair, sampling (inspection), and do nothing. The decision maker
would like to know the decision rule that minimizes total expected cost.
While the machine maintenance problem includes elements of partial observability where
testing (inspection) must be performed to gain information about the system, which is similar
to the sepsis management POMDP, other aspects of the problem greatly differentiate it from
this model. Most importantly, machine maintenance typically deals with a system that is
deteriorating. In contrast, the clinician is maintaining a system (patient health) that may be
deteriorating, improving, or staying the same. The set of possible actions also differs in that
the clinician does not consider repair (as the models to be described only consider testing
and discharge decisions at this time, not treatment decisions).
Derman [30] does not consider repair and demonstrates optimal inspection schedules for
equipment whose life is of a random length. However, the assumed deterioration of the
system plays a key role. In addition, replacement of the equipment returns the system to
its original new state. It is difficult to draw parallels between the replacement action and
the patient discharge action because the problems have differing objectives. The objective
of the models present in this dissertation is to maximize total expected life for an individual
patient over a finite horizon while the machine maintenance problem considers minimizing
the total cost of a production system over an infinite horizon.
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3.0 MODELING TESTING AND HOSPITAL DISCHARGE DECISIONS
(GENERAL MODEL)
As presented in the problem description in Chapter 1, the general model considers a patient
that at some point at or after hospital admission is suspected of having developed sepsis. This
model assumes that this patient is treated according to standard care while simultaneously
considering a subset of decisions made by the clinician in the treatment of this patient.
More specifically, the general model considers the clinician’s decision problem of when
to test for additional information about a patient’s health state in addition to the decision
problem of when to discharge the patient from the hospital in order to maximize the patient’s
expected survival over a finite horizon as measured from hospital admission. The model is
formulated as a finite-horizon POMDP, where the patient’s health state is characterized by
two vectors pertaining to completely and partially observable health state information. It
is assumed that throughout the patient’s stay in the hospital, the patient is being treated
according to standard methods of care.
At each stage before a decision is made, the clinician first observes the patient’s com-
pletely observable health state and the results of any tests that were ordered in the previous
stage. Based on these observations, the clinician then either decides to discharge the patient
from the hospital or to keep the patient in the hospital for one more stage. If the clinician
decides to keep the patient in the hospital, then the clinician must also decide whether or not
to order any tests to obtain additional information about the patient’s partially observable
health state variables. If a set of tests are ordered, their results are not known until the
beginning of the next time period.
The following model formulation can be used to determine the optimal action and re-
sulting expected survival over the remainder of the specified finite observation horizon for
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a patient at any stage in the patient’s treatment, based on the patient’s observable health
variables and the clinician’s belief as to what the patient’s partially observable health state
variables are based on previous test results and the patient’s current completely observable
health state. First, the following assumptions are made for this general model and all model
variants presented in this dissertation.
3.1 ASSUMPTIONS
Assumption 3.1.1 Markov property: It is assumed that the patient’s health variables
are Markovian in that their values at a specific decision epoch only depend on the patient’s
state and the action taken at the previous decision epoch.
Future research could consider expanding the state description to include additional history.
Assumption 3.1.2 Finite horizon: A finite-horizon model is utilized to facilitate the in-
corporation of time-dependent factors into the model. The model incorporates both a decision
horizon and an observation horizon. The decision horizon is used to reflect the short treat-
ment horizon associated with acute diseases like sepsis. The observation horizon considers
the time post-discharge during which death can be attributed to sepsis. Both of these horizons
are demonstrably finite and short.
Assumption 3.1.3 Finite, discrete state space: All patient health variables can be
represented as finite, discrete values.
Although many variables may appear to be continuous, they are often discretized naturally
in practice as a result of the measurement techniques used to assess their value.
Assumption 3.1.4 Testing delay: It is assumed that all test results are received at the
beginning of the stage immediately following the stage when the test(s) were ordered. There-
fore, if one or more tests are ordered, the patient cannot be discharged until the next time
period or later.
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Assumption 3.1.5 Test independence: It is assumed that the results of a test for a
particular health variable are only dependent on the true value of that health variable and are
independent of the true and observed values of all other health variables.
3.2 GENERAL MODEL FORMULATION
The following notation is used:
• N = {1, 2, . . . , N}: discrete stages at which a decision must be made by the clinician. If
a patient has not died and has not been discharged by stage N , it is assumed that the
patient is discharged at stage N . This dissertation defines a stage as one day; however,
the model is flexible enough to consider smaller time intervals (hours, for example) as
the data for solving such a model become available. Let t denote the current stage in
the model.
• T : the observation horizon, as measured from admission to the hospital, in which a
patient’s death is attributable to sepsis.
• ht: a vector describing the completely observable components of the patient’s health at
stage t. Let H be the set of all possible realizations of ht. The ordered elements of H
are represented as 1, 2, . . . , H,H +1, where H +1 represents the patient being dead and
is an absorbing state.
• yt: a vector describing the true values of the partially observable components of the
patient’s health at stage t. Let Y be the set of all possible realizations of yt. The ordered
elements of Y are represented as 1, 2, . . . , Y .
• δt: the set of tests ordered at time t. Let ∆ be the set of all possible combinations of
available tests, including ∅.
• c(δt): a scalar representing the cost of ordering test set δt at stage t (converted to patient
life days using methods from cost-effectiveness analysis [47]).
• ot+1: a vector describing the observed values of the partially observable components of
the patient’s health at stage t + 1 for tests ordered in stage t. Let O be the set of all
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possible realizations of ot+1. The ordered elements of O are represented as 1, 2, . . . , O. If
no tests were ordered in stage t, then ot+1 = ∅.
• at: the action chosen at stage t. Possible actions are to discharge the patient from the
hospital (D) or to continue treating the patient in the hospital according to standard
methods of care and order test set δt ∈ ∆ (Cδt). Note that the option to order no tests (∅)
is contained in ∆. Recall the assumption that when tests are ordered, the test results are
received at the beginning of the next period before the next decision is made. Therefore,
the patient cannot be discharged before the next period.
• ft(ht, yt, D): the expected (T − t)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage t with completely observable health vector ht and
partial observable health vector yt.
• rt(ht, pit, D): the expected (T − t)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage t with completely observable health vector ht and
belief vector pit, where rt(ht, pit, D) =
∑
yt∈Y ft(ht, yt, D)pit(yt).
• ft(ht, yt, Cδt): the expected reward (in patient life days) received for keeping a patient
with completely observable health vector ht and partially observable health vector yt at
time t in the hospital for one more stage and ordering test set δt.
• rt(ht, pit, Cδt): the expected reward (in patient life days) received for keeping a patient
with completely observable health vector ht and belief vector pit at time t in the hospital
for one more stage and ordering test set δt, where rt(ht, pit, Cδt) =
∑
yt∈Y ft(ht, yt, Cδt)pit(yt).
• fN(hN , yN): the expected (T −N)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage N with with completely observable health vector
hN and partially observable health vector yN .
• rN(hN , piN): the expected (T −N)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage N with with completely observable health vector
hN and belief vector piN , where rt(hN , piN) =
∑
yN∈Y fN(hN , yN)piN(yN).
• pt(ht+1, yt+1|ht, yt, at): the joint probability that the true values of the patient’s com-
pletely observable and partial observable heath vectors are ht+1 and yt+1, respectively,
at stage t+ 1 given that their respective values were ht and yt and action at was chosen
at stage t.
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• z(ot+1|yt+1, at): the probability of observing test results ot+1 at stage t+1 given that the
patient’s true partially observable health vector is yt+1 and action at was chosen at stage
t.
• pit: the belief vector. Let Πt denote all possible realizations of pit, where Π1 = Π2 =
. . . = ΠN = Π. Let pit(yt) denote the component of the belief vector corresponding to
the probability that the patient’s true partially observable health vector is yt ∈ Y at
stage t.
• βt(ht+1|ht, pit, at): the probability of observing completely observable health state ht+1 at
time t+ 1 given that at time t, the patient’s completely observable health state was ht,
the belief vector was pit, and action at was chosen, where
βt(ht+1|ht, pit, at) =
∑
yt+1∈Y
∑
yt∈Y
pt(ht+1, yt+1|ht, yt, at)pit(yt). (3.1)
• γt(ot+1|ht, pit, at): the probability of receiving observation vector ot+1 at time t+ 1 given
that the patient’s true completely observable health state was ht, the belief vector was
pit, and action at was chosen at time t, where
γt(ot+1|ht, pit, at) =
∑
yt+1∈Y
z(ot+1|yt+1, at)
∑
ht+1∈H
∑
ht∈H
∑
yt∈Y
pt(ht+1, yt+1|ht, yt, at)pit(yt).(3.2)
• U(pit+1|ot+1, ht+1, pit, at): the updating function used to update the belief vector pit+1
based on ot+1, the observation vector at stage t + 1, ht+1, the patient’s completely ob-
servable health vector at stage t + 1, pit, the belief vector at stage t, and at, the action
chosen at time t. Let U(pit+1(yt+1)|ot+1, ht+1, pit, at) denote the updating function used
to update component yt+1 of the belief vector, where
U(pit+1(yt+1)|ot+1, ht+1, pit, at) (3.3)
=
{
z(ot+1|yt+1,at)
∑
ht+1∈H
∑
ht∈H
∑
yt∈Y pt(ht+1,yt+1|ht,yt,at)pit(yt)
γt(ot+1|ht,pit,at) .
• Vt(ht, pit): the value function used to calculate the total expected reward (in patient life
days) at stage t when the patient’s truly observable health state is ht and the belief
vector is pit, where V
∗
t (ht, pit) denotes the optimal value function value.
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• A∗t (ht, pit): the set of optimal actions at stage t when the patient’s truly observable
health state is ht and the belief vector is pit, where a
∗
t (ht, pit) ∈ A∗t (ht, pit) is an action
that maximizes the value function Vt(ht, pit).
After action at is taken at stage t, an immediate expected reward rt(ht, pit, at) is received.
If at = D, the patient is discharged from the hospital and receives an expected reward,
rt(ht, pit, D). If at = Cδt , the patient remains in the hospital and receives an expected reward
rt(ht, pit, Cδt). At the same time the clinician orders test set δt, the results of which will be
received at the beginning of the next stage. After receiving the immediate expected reward,
the patient’s completely and partially observable health vectors transition to new values. At
the beginning of the next stage, if the patient has not died then the patient’s completely
observable health state and the results of any test ordered at stage t are observed by the
clinician.
Based on this information, each component of the belief vector, pit, is updated from stage
t to stage t + 1 using the updating function, U(pit+1|ot+1, ht+1, pit, at) as described in (3.3).
Note that if one or more tests were ordered at stage t, then the resulting observation vector,
ot+1, which denotes the values of the test results received at the beginning of stage t+1, are
used when updating the belief vector pit to pit+1, before a decision is made in stage t+ 1.
Let the optimal value function, V ∗t (ht, pit), be the total expected reward for time t onward
for a patient with completely observable health vector ht and belief vector pit at time t.
V ∗t (ht, pit) can then be defined recursively as follows.
V ∗N(hN , piN) = rN(hN , piN), for all piN ∈ Π and hN = 1, . . . , H, (3.4)
V ∗t (ht, pit) = max

rt(ht, pit, D),
rt(ht, pit, Cδt)− c(δt) +
∑
ht+1∈H βt(ht+1|ht, pit, at)
·∑ot+1∈O γt(ot+1|ht, pit, at)V ∗t+1(ht+1, U(pit+1|ht+1, ot+1, pit, at)),
for all pit ∈ Π, ht = 1, . . . , H, and t = 1, . . . , N − 1, and
V ∗t (H + 1, pit) = 0, for all pit ∈ Π and t ∈ N . (3.5)
This model is the most general problem considered in this dissertation. However, due to
the data requirements needed to solve even a modestly sized MDP or POMDP, simplified
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variants of this general model were developed to further explore both structural properties of
the model and computation experiments using patient-based data from the GenIMS study.
These variants are described in the following section.
3.3 SIMPLIFIED MODEL VARIANTS
Chapter 4 considers the most simplified variant of the general model in which the patient’s
health state is described by a single, completely observable variable, the patient’s Sepsis-
related Organ Failure Assessment (SOFA) score. This score considers many aspects of the
patient’s health state and is therefore an appropriate measure of completely observable pa-
tient health. This model is general enough to consider any single measure of patient health
in future research.
Chapter 5 extends Chapter 4 by considering a partially observable patient health state.
Similar to the previous chapter, however, the patient health state is still confined to a single
health variable, the value of a single cytokine level. Since the interactions between cytokines
are still under investigation and have not been completely analyzed for statistical dependen-
cies, it is not possible at this time to develop a more sophisticated POMDP model utilizing
multiple cytokine values. Also, due to the extensive data requirements needed to calcu-
late joint probability distributions for a multi-state model, exact solutions to a SOFA- and
cytokine-based model were not explored as part of this dissertation. Chapter 5 does, however,
explore heuristic approaches to developing SOFA- and cytokine-base decision policies.
Note that the MDP model presented in Chapter 4 is general enough to also consider
a cytokine-based MDP model. This is not explored in this dissertation, however, because
it will not provide clinically useful results. Similarly, while the POMDP model presented
in Chapter 5 is general enough to consider a SOFA-based POMDP, this model was not
considered because of its lack of clinical relevance.
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3.4 MODELING TEST ACCURACY
The general model and the simplified POMDP model presented in Chapter 5 utilize an
observation process that updates the clinician’s belief of the patient’s true health state based
on the values of one or more test results.
In both models, the clinician does not know the patient’s true health state with complete
certainty for at least one of two reasons. First, if the clinician decides not to order tests in
a given period, then the clinician will not have any information on the patient’s partially
observable health state, causing uncertainty. Second, even if the clinician orders a test and
observes its result, there may be error associated with the result.
Test error can be interpreted in two different ways. First, the result itself may be inac-
curate from a measurement standpoint. Accuracy in this case refers to the sensitivity and
specificity of the test. Alternatively, the interpretation of the test results may be inaccu-
rate. In other words, even if the test result is numerically correct, the interpretation of the
numerical result may not be completely accurate.
Since a test result may not be received in every stage and the test results that are
received may either be inaccurate themselves or interpreted inaccurately, the models use
a belief vector to describe a probability distribution over the possible true patient health
states, which corresponds the the clinician’s belief that the patient’s true health is in each
of the possible states. The model utilizes an observation probability matrix to relate the
observed values to the underlying health state. Then, using an initial estimate of the belief
variable, the current test results, and knowledge of the last action taken, Bayesian updating
is used to form a new estimate of the belief vector. The clinician’s decision is made based
on the value of this belief vector at each decision point.
The model presented in Chapter 5 considers the accuracy of cytokine testing from the
measurement perspective. Therefore, test error refers only to the inaccuracy between re-
ceiving a test result and it relationship to the true value of the patient’s cytokine level. A
more accurate model of testing inaccuracy would consider the clinician’s interpretation er-
ror in terms of translating the actual cytokine level to the underlying patient health state.
Unfortunately, the true relationship between these cytokine levels and the patient’s true
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underlying health state is not understood well enough to model this relationship, which is
needed in order to incorporate interpretation error into the model. As these relationships
are better understood, future research could consider interpretation error as an extension of
the models presented in this dissertation.
3.5 QUANTIFYING TESTING COST
Testing for cytokines has not yet been quantified in the literature as this is a new procedure
that has not yet been incorporated into standard practice. The cost of testing should include
not only the cost of the materials needed to perform the test and process the test results,
but also the time spent administering the test and reviewing and interpreting the results.
One could even consider the quality of life implications associated with frequent testing.
The focus of this dissertation is to investigate general testing and hospital discharge
strategies. Since testing cost is an important factor in these decisions, but has not yet been
quantified, the computational experiments presented in Section 5.4 provide results for a range
of testing costs. The reward function is calculated in units of patient life days; therefore,
the testing cost utilized in the problem instances is also represented in patient life days. To
convert actual dollars to life days, one could use a standard dollars-to-life days conversion
rate, as is commonly done in cost-effective analysis [48].
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4.0 MODELING HOSPITAL DISCHARGE POLICIES WITHOUT
CONSIDERING TESTING DECISIONS (A MARKOV DECISION PROCESS
APPROACH)
A simplified variant of the general model presented in Chapter 3, this model considers the
clinician’s decision problem of when to discharge an individual patient from the hospital
in order to maximize that patient’s expected survival over a finite observation horizon as
measured from hospital admission, where common values of this observation horizon include
30, 60, and 90 days [27, 90, 116]. The problem is formulated as a finite-horizon Markov
decision process to capture time dependencies among state transitions and rewards. In
addition to only considering the discharge decision, this model also assumes that a single
measure of patient health characterizes the health state and standard methods of care guide
patient treatment throughout the patient’s hospital stay. Therefore, at each decision point,
the clinician can choose either to continue treating the patient in the hospital with standard
care or to discharge the patient from the hospital. It is assumed that decisions are made at
the end of each time period. The work presented in this Chapter has been submitted for
publication [65].
4.1 MDP NOTATION
The following notation is used:
• N = {1, 2, . . . , N}: discrete stages at which a decision is made by the clinician, where
N is the treatment horizon. If a patient has not died and has not been discharged by
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stage N , it is assumed the patient is discharged at stage N . The finite-horizon model
captures time dependencies among state transitions, where the value of N depends on
the input data for computational experiments. This dissertation defines a stage as one
day; however, as the data for solving such a model become available, the model is flexible
enough to consider smaller time intervals (hours, for example).
• T : the observation horizon, as measured from admission to the hospital, in which a
patient’s death is attributable to sepsis.
• h: the patient’s health state vector. Let H be the set of all possible realizations of h in
order of decreasing health. The ordered elements of H are represented as 1, 2, . . . , H,H+
1, where H + 1 represents the patient being dead and is an absorbing state.
• at: the action taken at time t. The possible actions are to continue treating the patient
in the hospital (C) and to discharge the patient from the hospital (D).
• rt(h,D): the expected (T − t)-day survival (in patient life days) of a patient that is
discharged from the hospital on day t in health state h.
• rt(h,C): the expected reward (in patient life days) received for deciding at stage t to
keep a patient in health state h in the hospital for one more stage. This model uses an
expected reward for continuing of one day for all stages and states.
• rN(h): the expected (T − N)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage N in health state h.
• pt(j|h, a): the probability that the patient’s health state is j in stage t+1 given that the
patient’s health state is h in stage t and action a is chosen. Note that the process will
terminate with reward rt(H +1, C) = 0 if a patient transitions to the dead state or with
reward rt(h,D) if action D is chosen.
• Vt(h): the value function used to calculate the total expected reward (in patient life days)
for stage t onward when the system is in state h, where V ∗t (h) denotes the optimal value
function value. Thus, V ∗1 (h) will be the optimal total expected T − 1-day survival (in
days) of a patient that has just been admitted to the hospital in state h.
• A∗t (h): the set of optimal actions at stage t when the system is in state h, where a∗t (h) ∈
A∗t (h) is an action that maximizes the value function Vt(h).
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4.2 MDP MODEL FORMULATION
This problem can be formulated as the following optimality equations:
Vt(h) = max
rt(h,D), rt(h,C) +
H+1∑
j=1
pt(j|h,C)Vt+1(j)
 (4.1)
for h = 1, . . . , H and t = 1, . . . , N − 1,
VN(h) = rN(h), for h = 1, . . . , H, (4.2)
Vt(H + 1) = 0, for t = 1, . . . , N. (4.3)
The next section discusses the structure of the optimal value function in addition to present-
ing clinical conditions under which optimal non-stationary control-limit policies exist.
4.3 ANALYZING OPTIMAL HOSPITAL DISCHARGE POLICY
STRUCTURE FOR THE MDP MODEL
The mathematical framework of the MDP model allows for the analysis of the structure of
the model parameters and its optimal solution, providing insight into results that can be
expected in practice. For example, this section demonstrates the monotonicity of the value
function as formulated in (4.1) through (4.3). It will be demonstrated that as a patient
becomes sicker, the patient’s (T − t)-day expected survival does not increase. Conditions for
the existence of an optimal non-stationary control-limit policy are also presented. Relevant
proofs are included in the Appendix. First, the following definitions are provided.
4.3.1 Definitions
Definition [10] The N ×N transition probability matrix P (t), with entries [P (t)]hj, is said
to be IFR (Increasing Failure Rate) if the rows of P (t) are in increasing stochastic order,
that is, z(h) =
∑N
j=k[P (t)]hj is monotonically increasing in h for k = 1, . . . , N .
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Definition [89] Let X and Y be partially ordered sets and g(x, y) a real-valued function on
X × Y . The function g is said to be superadditive if for x+ ≥ x− in X and y+ ≥ y− in Y ,
g(x+, y+) + g(x−, y−) ≥ g(x+, y−) + g(x−, y+).
If the reverse inequality holds, the function is said to be subadditive.
The following assumptions are later verified in Section 4.4.4 for each of the problem
instances presented in Section 4.4.3.
4.3.2 Additional assumptions for the MDP model
Assumption 4.3.1 The patient health transition probability matrix P (t), with entries [P (t)]hj =
pt(j|h,C), is IFR for all t ∈ N .
Assumption 4.3.1 implies that for two patients in health states h and h+1, respectively, the
patient in health state h+1 is more likely to transition to a health state worse than h in the
next stage. In other words, sicker patients are more likely to progress to being even sicker
than are healthier patients.
Assumption 4.3.2 The reward function rt(h,D) is nonnegative and monotone decreasing
in h for all t ∈ N . It follows that the reward function rN(h) is also nonnegative and
monotone decreasing in h since a patient that has not died or been discharged by stage N
must be discharged at stage N .
Assumption 4.3.2 says that sicker patients have worse survival after discharge than healthier
patients.
Assumption 4.3.3 The reward function rt(h,C) is monotone decreasing in h for all t ∈ N .
Assumptions 4.3.2 and 4.3.3 imply that as a patient’s health degrades, the value of remaining
in the hospital for one additional day and the patient’s expected (T − t)-day survival after
discharge on day t do not increase.
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4.3.3 Mathematical structure of optimal hospital discharge policies
Under these assumptions, it can be shown that the optimal value function, V ∗t (h), is mono-
tonically decreasing in h. First, two supporting lemmas are introduced.
Lemma 4.3.4 (Adapted from Lemma 1 in [3]) Given Assumption 4.3.1 and a function,
V ∗t+1(h), that is monotone decreasing in h, the following inequalities hold for h = 1, . . . , H
and t = 1, . . . , N − 1,
h∑
j=1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j) ≥
h∑
j=1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(h), (4.4)
H+1∑
j=h+1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(j) ≥
H+1∑
j=h+1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(h+1). (4.5)
Proof For inequality (4.4): Assumption (4.3.1) requires that
h∑
j=0
pt(j|h) ≥
h∑
j=0
pt(j|h+ 1)
for h = 0 . . . , H. Therefore,
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
= [pt(0|h,C)− pt(0|h+ 1, C)]V ∗t+1(0) +
h∑
j=1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
≥ [pt(0|h,C)− pt(0|h+ 1, C)]V ∗t+1(1) +
h∑
j=1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j) (4.6)
= [pt(0|h,C)− pt(0|h+ 1, C)]V ∗t+1(1) + [pt(1|h,C)− pt(1|h+ 1, C)]V ∗t+1(1)
+
h∑
j=2
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
= [pt(0|h,C) + pt(1|h,C)− pt(0|h+ 1, C)− pt(1|h+ 1, C)]V ∗t+1(1)
+
h∑
j=2
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
≥ [pt(0|h,C) + pt(1|h,C)− pt(0|h+ 1, C)− pt(1|h+ 1, C]V ∗t+1(2)
+
h∑
j=2
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j), (4.7)
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where (4.6) follows because pt(0|h,C) ≥ pt(0|h+1, C), by Assumption (4.3.1), and V ∗t+1(0) ≥
V ∗t+1(1), by the initial assumption on V
∗
t+1(h). Similarly, (4.7) holds because pt(0|h,C) +
pt(1|h,C) ≥ pt(0|h + 1, C) + pt(1|h + 1, C) and V ∗t+1(1) ≥ V ∗t+1(2). The result follows when
the same procedure is applied for j = 2, . . . , h.
For inequality (4.5): Assumption (4.3.1) requires that
H+1∑
j=h+1
pt(j|h,C) ≤
H+1∑
j=h+1
pt(j|h+ 1, C)
for h = 0, . . . , H. Therefore,
H+1∑
j=h+1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
= [pt(H +1|h,C)− pt(H +1|h+1, C)]V ∗t+1(H +1)+
H∑
j=h+1
[pt(j|h,C)− pt(j|h+1, C)]V ∗t+1(j)
≥ [pt(H+1|h,C)−pt(H+1|h+1, C)]V ∗t+1(H)+
H∑
j=h+1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(j) (4.8)
= [pt(H + 1|h,C)− pt(H + 1|h+ 1, C)]V ∗t+1(H) + [pt(H|h,C)− pt(H|h+ 1, C)]V ∗t+1(H)
+
H−1∑
j=h+1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
= [pt(H + 1|h,C) + pt(H|h,C)− pt(H + 1|h+ 1, C)− pt(H|h+ 1, C)]V ∗t+1(H)
+
H−1∑
j=h+1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
≥ [pt(H + 1|h,C) + pt(H|h,C)− pt(H + 1|h+ 1, C)− pt(H|h+ 1, C)]V ∗t+1(H − 1)
+
H−1∑
j=h+1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j), (4.9)
where (4.8) follows because pt(H +1|h,C) ≤ pt(H +1|h+1, C), by Assumption (4.3.1), and
V ∗t+1(H) ≥ V ∗t+1(H + 1), by the initial assumption on V ∗t+1(h). Similarly, (4.9) holds because
pt(H+1|h,C)+pt(H|h,C) ≤ pt(H+1|h+1, C)+pt(H|h+1, C) and V ∗t+1(H−1) ≥ V ∗t+1(H).
The result follows when the same procedure is applied for j = h+ 1, . . . , H − 1.
Lemma 4.3.5 (Adapted from Lemma 2 in [3]) Given Assumption 4.3.1 and a function,
V ∗t+1(h), that is monotone decreasing in h for t = 1, . . . , N − 1,
∑H+1
j=1 pt(j|h,C)V ∗t+1(j) ≥∑H+1
j=1 pt(j|h+ 1, C)V ∗t+1(j) for h = 1, . . . , H and t = 1, . . . , N − 1.
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Proof Note that
H+1∑
j=0
pt(j|h,C)V ∗t+1(j)−
H+1∑
j=0
pt(j|h+ 1, C)V ∗t+1(j)
=
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j) +
H+1∑
j=h+1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j)
≥
h∑
j=0
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(h)+
H+1∑
j=h+1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(h+1) (4.10)
=
h∑
j=0
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(h)+
 H+1∑
j=h+1
pt(j|h,C)−
H+1∑
j=h+1
pt(j|h+ 1, C)
V ∗t+1(h+1)
=
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(h)
+
1− h∑
j=0
pt(j|h,C)
−
1− h∑
j=0
pt(j|h+ 1, C)
V ∗t+1(h+ 1)
=
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(h)−
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(h+ 1)
= [V ∗t+1(h)− V ∗t+1(h+ 1)]
h∑
j=0
[pt(j|h,C)− pt(j|h+ 1, C)], (4.11)
where (4.10) follows from Lemma 4.3.4. Following from the monotonicity assumption on
V ∗t (h) and Assumption (4.3.1), V
∗
t+1(h) − V ∗t+1(h + 1) and
∑h
j=0[pt(j|h,C) − pt(j|h + 1, C)]
are nonnegative. Therefore, the quantity in (4.11) is also nonnegative and the desired result
follows.
Theorem 4.3.6 Under Assumptions 4.3.1, 4.3.2, and 4.3.3 for h = 1, . . . , H, V ∗t (h) ≥
V ∗t (h+ 1) for all t ∈ N .
Proof (By induction)
From Assumption 4.3.2 it follows that V ∗N(h) ≥ V ∗N(h+1) since V ∗N(h) = rN(h) for all h ∈ H.
Now suppose that V ∗n (h) ≥ V ∗n (h + 1) for h = 1, . . . , H and for n = t + 1, . . . , N − 1. It
remains to show that V ∗t (h) ≥ V ∗t (h+ 1) for h = 1, . . . , H. Note that
V ∗t (h) = max
rt(h,D), rt(h,C) +
H+1∑
j=1
pt(j|h,C)V ∗t+1(j)
 , and (4.12)
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V ∗t (h+ 1) = max
rt(h+ 1, D), rt(h+ 1, C) +
H+1∑
j=1
pt(j|h+ 1, C)V ∗t+1(j)
 . (4.13)
If V ∗t (h + 1) = rt(h + 1, D), then by definition of V
∗
t (h) and Assumption 4.3.2, V
∗
t (h) ≥
rt(h,D) ≥ rt(h+ 1, D) = V ∗t (h+ 1) and the result follows. Otherwise,
V ∗t (h)−V ∗t (h+1) ≥ rt(h,C)− rt(h+1, C)+
H+1∑
j=1
pt(j|h,C)V ∗t+1(j)−
H+1∑
j=1
pt(j|h+1, C)V ∗t+1(j)
≥
H+1∑
j=1
pt(j|h,C)V ∗t+1(j)−
H+1∑
j=1
pt(j|h+ 1, C)V ∗t+1(j) (4.14)
where (4.3.3) follows from the value functions (4.12) and (4.13) and the inequality (4.14)
follows from Assumption 4.3.3. Following from the induction assumptions and Lemma 4.3.5,
(4.14) is nonnegative and the desired result follows.
This result demonstrates the intuitive conclusion that as a patient’s health degrades, the
patient’s expected T -day survival does not improve.
In addition to showing that structure exists for the model value function, it is also desir-
able to extend these results by demonstrating structure for the resulting optimal solution.
Of particular interest for this type of model is to demonstrate the existence of a control-limit
policy.
Theorem 4.3.7 presents a general condition for the existence of a control-limit policy.
Theorem 4.3.7 There exists an optimal non-stationary control-limit policy in h if
rt(h,D)−rt(h+1, D) ≥ rt(h,C)−rt(h+1, C)+
H+1∑
j=1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(j), (4.15)
for h = 1, . . . , H and t = 1, . . . , N −1. In other words, for each t ∈ N there exists a state h∗t
(the control limit) such that a∗t (1) = · · · = a∗t (h∗t − 1) = D and a∗t (h∗t ) = a∗t (h∗t + 1) = · · · =
a∗t (H + 1) = C.
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Proof (By contradiction)
Recall that
V ∗t (h) = max
rt(h,D), rt(h,C) +
H+1∑
j=1
pt(j|h,C)V ∗t+1(j)
 . (4.16)
For a fixed value of t, assume that for some h, a∗t (h) = C. Now suppose that a
∗
t (h+1) = D.
This implies that
rt(h,D) ≤ rt(h,C) +
H+1∑
j=1
pt(j|h,C)V ∗t+1(j) (4.17)
and
rt(h+ 1, D) > rt(h+ 1, C) +
H+1∑
j=1
pt(j|h+ 1, C)V ∗t+1(j).
Therefore,
rt(h,D)−rt(h+1, D) < rt(h,C)−rt(h+1, C)+
H+1∑
j=1
[pt(j|h,C)−pt(j|h+1, C)]V ∗t+1(j), (4.18)
which contradicts Condition (4.15). Therefore, a∗t (h+1) must equal C, completing the proof.
Condition (4.15) can be interpreted as follows: the marginal decrease in a patient’s (T − t)-
day expected survival in sequential health states must be no less than the marginal decrease
in a patient’s immediate reward received for remaining in the hospital for one more day plus
the total expected reward for the remaining time the patient is in the hospital.
Note that Condition (4.15) implies that in order for a control-limit policy to exist, the
function
wt(h, a) = rt(h, a) +
H+1∑
j=1
pt(j|h, a)V ∗t+1(j),
must be superadditive for h and a, where h has the natural ordering 1, 2, . . . , H + 1 and
C ≥ D. The traditional method of demonstrating that wt(h, a) is superadditive is to
show that both rt(h, a) and
∑H+1
j=1 pt(j|h, a)V ∗t+1(j) are superadditive. Proposition 4.3.8
demonstrates that rt(h, a) is superadditive; unfortunately, Proposition 4.3.9 shows that∑H+1
j=1 pt(j|h, a)V ∗t+1(j) is subadditive.
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Proposition 4.3.8 The function, rt(h, a), is superadditive.
Proof By Assumption 4.3.2,
rt(h,D) ≥ rt(h+ 1, D).
As stated in the model formulation, rt(h,C) = rt(h+ 1, C) = 1, therefore,
rt(h,D) + rt(h+ 1, C) ≥ rt(h,C) + rt(h+ 1, D),
which is superadditive by Definition 4.3.1 and the assumed ordering of states and actions,
thus completing the proof.
Proposition 4.3.9 The function,
∑H+1
j=1 pt(j|h, a)V ∗t+1(j), is subadditive.
Proof By Lemma 4.3.5,
H+1∑
j=1
pt(j|h+ 1, C)V ∗t+1(j) ≤
H+1∑
j=1
pt(j|h,C)V ∗t+1(j).
By definition of the model, the process terminates if the patient is discharged. In other
words,
∑H+1
j=1 pt(j|h,D) =
∑H+1
j=1 pt(j|h+ 1, D) = 0 for all h ∈ H. Therefore,
H+1∑
j=1
pt(j|h+ 1, C)V ∗t+1(j) +
H+1∑
j=1
pt(j|h,D)V ∗t+1(j)
≤
H+1∑
j=1
pt(j|h,C)V ∗t+1(j) +
H+1∑
j=1
pt(j|h+ 1, D)V ∗t+1(j),
which is subadditive by Definition 4.3.1 and the assumed ordering of states and actions, thus
completing the proof.
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Redefining the ordering of the states and/or actions would only reverse the superadditivity
and subadditivity of rt(h, a) and
∑H+1
j=1 pt(j|h, a)V ∗t+1(j). Since the traditional proof will not
work for this model, it is left to demonstrate a condition under which the superadditivity
of rt(h, a) overcomes the subadditivity of
∑H+1
j=1 pt(j|h, a)V ∗t+1(j), to result in a superadditive
wt(h, a). Theorem 4.3.10 revises Condition (4.15) by incorporating clinical knowledge to
eliminate the dependence on V ∗t+1(h). First, ∆h is defined to be the maximum decrease
between health states h and h + 1 in a patient’s total expected reward for the remaining
time that the patient is in the hospital, where
H+1∑
j=1
[pt(j|h,C)− pt(j|h+ 1, C)]V ∗t+1(j) ≤ ∆h.
Using this information, Theorem 4.3.10 presents a sufficient condition for the existence of a
control-limit policy that is independent of the value function, V ∗t+1(h).
Theorem 4.3.10 There exists an optimal non-stationary control-limit policy in h if
rt(h,D)− rt(h,C)− [rt(h+ 1, D)− rt(h+ 1, C)] ≥ ∆h, (4.19)
for h = 1, . . . , H and t = 1, . . . , N − 1.
The proof of Theorem 4.3.10 is similar to the proof of Theorem 4.3.7 and is therefore omitted.
Unfortunately, Condition (4.19) is too restrictive for reasonable values of ∆h and does not
consistently hold for the data tested in this dissertation. The exploration of less restrictive
sufficient conditions is left to future research. The next section explores the existence of
control-limit policies for this model through various computational experiments.
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4.4 EXPLORING HOSPITAL DISCHARGE POLICIES USING
PATIENT-BASED DATA
One of the aims of this dissertation is to explore the structure of hospital decision policies
through the use of computational experiments for patients with sepsis with the hope of
being able to suggest general strategies for patient discharge. Due to the complexity of the
disease and the availability of data at this time, the model state space is defined by a single
parameter, the total Sepsis-related Organ Failure Assessment (SOFA) score. This score is a
reasonable approximation for patient health because, as will be discussed in Section 4.4.2,
this score is calculated based on the complex interactions between multiple aspects of the
patient’s health, all of which were captured as part of the GenIMS trial. The model was
solved using the standard backward induction algorithm [89] presented in Appendix C.
4.4.1 MDP data sources
The GenIMS trial data contains static and dynamic variables for 2320 patients. These pa-
tients were identified by the GenIMS investigators as potentially having community-acquired
pneumonia (CAP). Of these patients, 2032 were admitted to the hospital and went on to
develop varying degrees of sepsis. The computational experiments presented in this section
utilize a sample of 2025 patients, with seven patients being excluded from the GenIMS in-
patient cohort due to missing or irregular data. Static variables such as age and race are
provided for each patient. Dynamic health variables are available on a daily basis, where
missing data were estimated utilizing a clinically derived algorithm that combines last ob-
servation carried forward and other clinically based interpolation methods, as agreed upon
by the GenIMS investigator team [45].
4.4.2 SOFA score
The patient’s health state is represented by the total SOFA score, an integer value ranging
between 0 and 24, where 24 corresponds to the sickest health state. The score was developed
by the Working Group on Sepsis-related Problems of the European Society of Intensive
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Care Medicine to describe quantitatively the degree of organ dysfunction/failure over time
[112]. The correlation between organ dysfunction and mortality makes the SOFA score an
appropriate descriptor of patient health in a model of severe sepsis and its use is supported by
previous models of severe sepsis in the literature that have used the SOFA score to describe
patient health [24, 40].
Total SOFA is calculated based on six component scores that evaluate different organ
systems (respiratory, coagulation, liver, central nervous system, renal, and cardiac). There-
fore, even though total SOFA is a single value, the score actually captures a wide range of
patient health variables. The daily component SOFA scores and the resulting total SOFA
scores were calculated by the GenIMS investigators for all patients in the GenIMS cohort. By
capturing the time-varying nature of each patient’s SOFA scores in the transition probabili-
ties used as input to the model, the model captures the evolution of patient health through
all stages of the disease and the patient’s hospital stay.
Due to data sparseness, the 25 total SOFA score values are aggregated into four patient
health states {0,1}, {2,3}, {4,5,6,7}, {8,. . .,24}, and defined as aggregated health states 1, 2,
3, and 4, respectively. This aggregation was chosen to capture changes in the SOFA score for
those levels at which clinicians would consider the discharge decision. Scores of 8 or greater
indicate a disease severity that would make the discharge decision improbable.
4.4.3 Problem instances considering various age/race cohorts
Based on conventions in the literature [22, 23, 24, 50, 62], the values N = 30 days and T = 90
days are used. Since age and race have been determined to be significant predictors of patient
mortality [58, 62], these static variables are used to define the eleven problem instances
described in Table 4.1. The age breaks (45, 65) used to describe the instances follow the
conventions in [24]. Note that the instances are further stratified by race (Caucasian, non-
Caucasian). Due to the small sample sizes associated with non-Caucasian patients under 65
years of age, not all combinations of age and race groups could be tested with the available
data.
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Table 4.1: Description of MDP Problem Instances
Instance Sample Size Age Race Stationary During Periods
1 468 < 65 Caucasian 1-3, 4-7, 8-29
2 1158 ≥ 65 Caucasian 1-3, 4-7, 8-29
3 273 < 65 non-Caucasian 1-3, 4-7, 8-29
4 126 ≥ 65 non-Caucasian 1-3, 4-7, 8-29
5 242 < 45 all 1, 2-9, 10-29
6 499 [45, 65] all 1, 2-9, 10-29
7 1284 ≥ 65 all 1, 2-9, 10-29
8 242 < 45 all 1-3, 4-7, 8-29
9 499 [45, 65] all 1-3, 4-7, 8-29
10 741 < 65 all 1-3, 4-7, 8-29
11 1284 ≥ 65 all 1-3, 4-7, 8-29
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The far right column of Table 4.1 describes a third component of the problem instances.
Due to data sparsity, the transition probabilities and rewards are assumed to be piece-wise
constant over specific stages as defined in the far right column of Table 4.1, but are allowed
to be time-varying between the grouped stages. For example, problem instance 2 considers
Caucasian patients that are age 65 or older. By assumption, the transition probabilities and
rewards for this problem instance are stationary during stages 1 through 3, stages 4 through
7, and stages 8 through 29, but can be time-varying between stages 3 and 4 and between
stages 7 and 8. Note that there are two different groupings used to define different problem
instances, (1-3, 4-7, 8-29) and (1, 2-9, 10-29). The former is based on the clinical expertise
of the coauthors. The latter definition is similar to that used by Clermont et al. [24].
These instances provide valuable insights into the effect of hospital length of stay on the
hospital discharge decision for patients of varying age and race. These results are described
in more detail in the next section.
4.4.4 Hospital discharge policy results and clinical interpretation
Table 4.2 presents the optimal policy for problem instance 2 including the optimal value
function value and the optimal action for each stage and state. The optimal value function
value, V ∗t (h), represents the (90 − t)-day expected survival of a patient in state h at stage
t given that the clinician chooses the optimal action in the current stage and in all stages
moving forward. For example, for a patient in aggregated health state 2 on day 5, the
optimal action is to Continue with an expected 85-day survival of 71.9 days given that the
clinician chose to keep the patient in the hospital and then act optimally in all future stages.
The optimal action to take at each stage and for each state is interpreted for problem
instance 2 as follows. During days 1, 2, and 3, it is optimal to discharge patients in aggregated
health states 1 and 2 (corresponding to a SOFA score of 0, 1, 2, or 3). For patients in all
other aggregated health states (corresponding to a SOFA score of 5 or greater), it is optimal
to keep the patient in the hospital for one additional day. During days 4, 5, and 6, it is
optimal to discharge patients in the healthiest aggregated state only (corresponding to a
SOFA score of 0 or 1) and to keep all other patients (corresponding to a SOFA score of
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2 or greater) in the hospital for one additional day. Finally, during days 7 through 29, it
is optimal to discharge all but the sickest patients and keep the remaining patients in the
hospital for one more day (corresponding to SOFA scores of 0 through 7 and then 8 through
24, respectively).
This optimal solution is a control-limit policy. It is interesting to note that the control
limit for this instance is time varying. For example, a patient that has not been discharged
by day 3 and that is in aggregated state 2 in day 4 would not be discharged under this
policy. This means that the patient was in an aggregated health state of 3 or greater in all
days prior to day 4 (or the patient would have been discharged previously). This policy is
intuitive, because patients that are sicker may need to remain in the hospital for a longer
period of time, even though they appear to improve over time. Recall that these policies are
determined as a result of the time-varying transition probabilities and rewards used as input
data to the model. These time-dependent inputs are an essential component of a robust
model of sepsis progression [24].
For days 7 through 29, only patients in the sickest health state should be kept in the
hospital, corresponding to similar results presented in the literature. For example, Halm et
al. [50] found that the median time to overall clinical stability in patients with CAP was
between 3 days for the most lenient definition of clinical stability and 7 days for the most
conservative definition. Studies looking at intensive care unit (ICU) length of stay for sepsis
patients found the median length of stay to be between 7 and 14 days [24, 93]. Given that
the current trend in research is to find ways to reduce excessively long ICU and hospital
stays, the results found through this analysis are quite promising. Therefore, while this type
of policy does not hold exactly for all stages in all problem instances, it does suggest an
easy-to-implement decision making strategy.
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Table 4.2: Optimal Solution to Problem Instance 2 (D = Discharge, C = Continue)
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 85.367 83.606 63.617 31.023 D D C C
2 84.408 82.667 61.567 28.743 D D C C
3 83.449 81.727 58.123 25.187 D D C C
4 76.947 72.695 59.095 17.014 D C C C
5 76.053 71.632 57.770 16.271 D C C C
6 75.158 70.561 56.167 14.861 D C C C
7 74.263 69.541 54.269 11.550 D D D C
8 67.739 57.245 45.556 6.415 D D D C
9 66.913 56.547 45.000 6.353 D D D C
10 66.087 55.849 44.444 6.291 D D D C
11 65.261 55.151 43.889 6.229 D D D C
12 64.435 54.453 43.333 6.167 D D D C
13 63.609 53.755 42.778 6.105 D D D C
14 62.783 53.057 42.222 6.043 D D D C
15 61.957 52.358 41.667 5.980 D D D C
16 61.130 51.660 41.111 5.918 D D D C
17 60.304 50.962 40.556 5.856 D D D C
18 59.478 50.264 40.000 5.794 D D D C
19 58.652 49.566 39.444 5.732 D D D C
20 57.826 48.868 38.889 5.670 D D D C
21 57.000 48.170 38.333 5.608 D D D C
22 56.174 47.472 37.778 5.545 D D D C
23 55.348 46.774 37.222 5.483 D D D C
24 54.522 46.075 36.667 5.418 D D D C
25 53.696 45.377 36.111 5.349 D D D C
26 52.870 44.679 35.556 5.261 D D D C
27 52.043 43.981 35.000 5.112 D D D C
28 51.217 43.283 34.444 4.749 D D D C
29 50.391 42.585 33.889 3.648 D D D C
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Table 4.3 provides a summary of the optimal action by day and state for every problem
instance. Control-limit policies are indicated in bold text. For example, control-limit policies
exist for every stage and state for problem instances 6 and 9 in addition to problem instance
2. The optimal policies for most of the other problem instances are of control-limit type for
the majority of states and stages. For example, problem instance 3 has a control-limit policy
for all days except day 29 and problem instance 11 follows this type of policy for all days
except days 5 and 6. Problem instances 5 and 8, however, vary further from the control-limit
policy structure. For instance 5, the control-limit policy structure does not hold for day 9
on and for instance 8, a control-limit type policy exists in days 1, 2, 3, and 29 only.
Table 4.4 lists how the assumptions and conditions presented in Section 4.3 hold for each
problem instance. For example, Assumption 4.3.1 does not hold for problem instance 4, while
Assumption 4.3.3 does hold for this instance. It is interesting to note that a control-limit
policy does not exist for those instances for which one or more assumptions does not hold.
Other possible reasons for the deviations from the non-stationary control-limit policy
structure appear to be attributable to both cohort sample size and definition. For example,
even though problem instance 7 has the largest sample size (1284) of all problem instances,
the patients included in this sample are not stratified by race. However, when patients are
separated by race (i.e., into problem instances 2 and 4), the new instances follow or closely
follow the control-limit policy structure. Since cohort 4 only has a sample size of 126 patients,
data sparseness may be the source of any policy deviations.
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Table 4.3: Optimal Solutions (Problem Instances 1 Through 11)
Instance Days
and Action: 1 2 3 4 5-6 7 8 9 10-26 27-28 29
1 D 1,2,3 1,2,3 1,2,3 2,3 2,3 1,2,3 1,3 1,3 1,3 1,3 1,3
C 4 4 4 1,4 1,4 4 2,4 2,4 2,4 2,4 2,4
2 D 1,2 1,2 1,2 1 1 1,2,3 1,2,3 1,2,3 1,2,3 1,2,3 1,2,3
C 3,4 3,4 3,4 2,3,4 2,3,4 4 4 4 4 4 4
3 D 1,2,3 1,2,3 1,2,3 1 1 1 1 1 1 1 1,3
C 4 4 4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 2,4
4 D 1 1 1 2,3 2,3 1,2,3 1 1 1 1 1,3
C 2,3,4 2,3,4 2,3,4 1,4 1,4 4 2,3,4 2,3,4 2,3,4 2,3,4 2,4
5 D 1,2,3 1,2,3 2,3 2,3 2,3 2,3 2,3 3 3 3 3
C 4 4 1,4 1,4 1,4 1,4 1,4 1,2,4 1,2,4 1,2,4 1,2,4
6 D 1 1 1 1 1 1 1 1,2,3 1 1 1
C 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4 4 2,3,4 2,3,4 2,3,4
7 D 2 1,2 1,3 1,3 1,3 1,3 1,3 1,2,3 1,2 1,2 1,2
C 1,3,4 3,4 2,4 2,4 2,4 2,4 2,4 4 3,4 3,4 3,4
8 D 1,2,3 1,2,3 1,2,3 3 3 3 3 3 3 3 1,2,3
C 4 4 4 1,2,4 1,2,4 1,2,4 1,2,4 1,2,4 1,2,4 1,2,4 4
9 D 1,2,3 1,2,3 1,2,3 1,2 1,2 1,2,3 1 1 1 1 1
C 4 4 4 3,4 3,4 4 2,3,4 2,3,4 2,3,4 2,3,4 2,3,4
10 D 1,2,3 1,2,3 1,2,3 1,2 1,2 1,2,3 1 1 1 1,3 1,3
C 4 4 4 3,4 3,4 4 2,3,4 2,3,4 2,3,4 2,4 2,4
11 D 1,2 1,2 1,2 1 1,3 1,2,3 1,2,3 1,2,3 1,2,3 1,2,3 1,2,3
C 3,4 3,4 3,4 2,3,4 2,4 4 4 4 4 4 4
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Table 4.4: Verification of Assumptions and Conditions from Section 4.2
Assumption Assumption Assumption Condition Control-limit
Instance 4.3.1 satisfied? 4.3.2 satisfied? 4.3.3 satisfied? 4.15 satisfied? Policy?
1 yes yes yes no no
2 yes yes yes no yes
3 yes yes yes no close
4 no no yes no no
5 no no yes no no
6 yes yes yes no yes
7 yes yes yes no no
8 yes no yes no no
9 yes yes yes no yes
10 yes yes yes no no
11 yes yes yes no close
4.5 CONCLUSIONS
Through mathematical analysis and computational experiments, study of this model found
that optimal hospital discharge strategies for patients with pneumonia-related sepsis tend to
follow a non-stationary control-limit type policy structure. These types of policies have an
obvious advantage in that they are easy to understand and can be used to standardize an
otherwise complicated and ad-hoc procedure. Introducing the medical community to this
type of policy structure is the first step in standardizing the hospital discharge decision.
There are limitations, however, to describing patient health by a single dimension, such
as total SOFA score. Future work will explore more complex state descriptions, such as those
that include the component SOFA scores, which are necessary before such models can inform
clinical practice. As more data become available, the model presented in this dissertation can
be used to provide increasingly accurate values for the health-based non-stationary control
limits. Clearly, additional data would help to resolve any issues with data sparseness and
would allow for the testing of additional cohort stratifications.
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For example, in addition to age and race, gender has also been cited as a key predictor
of patient mortality among patients with severe sepsis. Additional data would allow for the
testing of age, race, and gender cohorts.
The following chapter extends this model by incorporating testing decisions into the
model. In this second model, the patient health state is no longer characterized by the
SOFA score, rather the value of a single cytokine level is used as a predictor of patient
health. While a more realistic model would use both SOFA and the cytokine level, data
availability and computational complexity limit current capabilities. Chapter 5, however,
will explore heuristic methods for combining the solutions from both models.
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5.0 MODELING TESTING AND HOSPITAL DISCHARGE DECISIONS (A
PARTIALLY OBSERVABLE MARKOV DECISION PROCESS APPROACH)
Extending the model presented in Chapter 4, this model considers the clinician’s decision
problem of when to test for cytokine information in addition to the decision problem of
when to discharge the patient from the hospital in order to maximize the patient’s expected
survival over a finite observation horizon as measured from hospital admission. The model
is formulated as a finite-horizon POMDP, where the patient’s true health state can only be
observed through an inaccurate testing procedure. As a simplified variant of the general
model presented in Chapter 3, the patient health state is represented by a single variable
that measures the value of a single cytokine level. It is assumed that throughout the patient’s
stay in the hospital, the patient is being treated according to standard methods of care. At
each decision point, the clinician can decide to continue treating the patient in the hospital
using standard care without testing (C), continue treating the patient in the hospital using
standard care and also order a cytokine test (O), or discharge the patient from the hospital
without testing (D). It is assumed that when a test is ordered, its result is not known until
the beginning of the next time period. Therefore, if a cytokine test has been ordered for a
patient, the patient will remain in the hospital for at least one more time period. The next
stage’s decision is made after the test result ordered in the previous stage is observed.
In this model, the patient’s true health state is modeled as the value of a single cytokine
level. This level can take on one of two values: low (L) or high (H). After a test is ordered,
the clinician will observe either a L or H value, which relate probabilistically to the true
underlying cytokine level through the observation probability matrix (i.e., the accuracy of
the test). A low cytokine value is correlated with a high probability of patient survival [63];
however, it does not indicate patient survival with complete certainty. This uncertainty is
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captured in the expected survival calculation used for the reward function. In the model it
is assumed that the patient’s cytokine level cannot be known without testing, testing is done
only when action O is chosen, and test results are received at the beginning of the next time
period.
5.1 POMDP NOTATION
The following notation is used:
• N = {1, 2, . . . , N}: discrete stages at which a decision must be made by the clinician,
where N is the treatment horizon. If a patient has not died and has not been discharged
by stage N , it is assumed that the patient is discharged at stage N . This dissertation
defines a stage as one day; however, the model is flexible enough to consider smaller time
intervals (hours, for example) as the data for solving such a model become available. Let
t denote the current stage in the model.
• T : the observation time horizon used to measure patient survival from hospital admission.
• yt: a scalar describing the true value of the patient’s cytokine level. It is assumed that
yt can take on one of three values: low (L), high (H), or dead.
• ot: a scalar describing the observed value of the patient’s cytokine level. If the patient
has died, then ot = dead; otherwise, if a test is ordered, it is assumed that ot can take
on one of two values: low (L) or high (H). When no test result is received, let ot = ∅.
• at: the action taken. Possible actions are to continue treating the patient in the hospital
without ordering a cytokine test (C), to continue treating the patient in the hospital
and order a cytokine test (O), or to discharge the patient from the hospital (D). It is
assumed that when a cytokine test result is ordered, the test result is received at the
beginning of the next period before the next decision is made. Therefore, the patient
cannot be discharged before the next period. If the decision is made to discharge the
patient from the hospital, the patient transitions out of the model.
• c: a scalar representing the cost of ordering a cytokine test (converted to patient life days
using methods from cost-effectiveness analysis [47]).
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• ft(yt, D): the expected (T − t)-day survival (in patient life days) of a patient that is
discharged from the hospital at stage t with true health state yt. Note that ft(dead, D) =
0.
• rt(pit, D): the expected (T − t)-day survival (in patient life days) of a patient that
is discharged from the hospital at stage t with belief variable pit, where rt(pit, D) =
ft(L,D)pit + ft(H,D)(1− pit).
• ft(yt, O): the expected reward (in patient life days) received for keeping a patient with
true health state yt at time t in the hospital for one more stage and ordering a cytokine
test. Note that ft(dead, O) = 0.
• rt(pit, O): the expected reward (in patient life days) received for keeping a patient with
belief variable pit at time t in the hospital for one more stage and ordering a cytokine
test, where rt(pit, O) = ft(L,O)pit + ft(H,O)(1− pit).
• ft(yt, C): the expected reward (in patient life days) received for keeping a patient with
true health state yt at time t in the hospital for one more stage. Note that ft(dead, C) = 0.
• rt(pit, C): the expected reward (in patient life days) received for keeping a patient
with belief variable pit at time t in the hospital for one more stage, where rt(pit, C) =
ft(L,C)pit + ft(H,C)(1− pit).
• fN(yt): the expected (T−N)-day survival of a patient that is discharged from the hospital
at stage N with true health state yt. Note that fN(dead) = 0.
• rN(piN): the expected (T − N)-day survival of a patient that is discharged from the
hospital at stage N with belief variable piN , where rN(piN) = fN(L)piN + fN(H)(1−piN).
• pt(yt+1|yt, at): the probability that the patient’s true health state is yt+1 at stage t + 1
given that at stage t, the patient’s true health state was yt, and action at was chosen. Note
that pt(dead|dead, ·) = 1 and that the process will terminate with reward ft(dead, ·) = 0
if the patient dies before the next time period.
• z(ot+1|yt+1, at): the test accuracy, i.e., the probability of observing cytokine level ot+1 at
stage t+ 1 when the patient’s true cytokine level is yt+1 at stage t+ 1 and action at was
chosen at stage t. Note that z(dead|dead, ·) = 1 and that z(L|dead, ·) = z(H|dead, ·) =
z(∅|dead, ·) = 0.
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• pit: the probability that the patient’s true cytokine level is low (yt = L) at stage t given
that the patient is still alive at stage t.
• γt(ot+1|pit, at): the probability of observing cytokine level ot+1 at time t + 1 given that
the belief variable was pit and action at was taken at time t, where
γt(ot+1|pit, at) =
∑
yt+1∈{L,H,dead}
z(ot+1|yt+1, at)[pt(yt+1|L, at)pit + pt(yt+1|H, at)(1− pit)].
• U(pit+1|ot+1, pit, at): the updating function used to update the belief variable pit to pit+1
based on ot+1, the observation at stage t+1, pit, the belief variable at time t, and at, the
action taken at time t.
• Vt(pit): the value function used to calculate the total expected reward (in patient life
days) at stage t when the patient is alive and in health state pit, where V
∗
t (pit) denotes
the optimal value function value.
• A∗t (pit): the set of optimal actions at stage t when the system is in state pit, where
a∗t (pit) ∈ A∗t (pit) is an action that maximizes the value function Vt(pit).
After action at is taken at stage t, an immediate expected reward rt(pit, at) is received.
If at = D, the patient is discharged and receives an expected reward, rt(pit, D). If at = O,
the clinician orders a cytokine test, the patient receives an expected reward rt(pit, C) (in
patient life days), and the patient’s core health state transitions to a new value, which
includes the possibility of patient death. Finally, if at = C, no test is ordered, the patient
receives an expected reward rt(pit, C) (in patient life days), and the patient’s core health
state transitions to a new value, which includes the possibility of patient death. If a patient
dies (i.e., yt+1 = ot+1 = dead), it is assumed that death occurs at the beginning of the next
stage and that the patient exits the model and does not accumulate any future rewards. If
the patient does not die, the belief variable, pit, is updated from stage t to stage t+ 1 using
the updating function, U(pit+1|ot+1, pit, at), which performs the update using the observation
ot+1 from stage t+ 1, where
U(pit+1|ot+1, pit, at) =

z(ot+1|L)[pt(L|L,at)pit+pt(L|H,at)(1−pit)]
γt(ot+1|pit,at) , if ot+1 ∈ {H,L};
pt(L|L, at)pit + pt(L|H, at)(1− pit), if ot+1 = ∅.
(5.1)
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5.2 POMDP MODEL FORMULATION
Let the optimal value function, V ∗t (pit), be the total expected reward for a living patient with
belief variable pit for time t onward. V
∗
t (pit) can then be defined recursively as follows.
V ∗N(piN) = rN(piN), for all piN ∈ Π (5.2)
V ∗t (pit) = max

rt(pit, D),
rt(pit, O)− c+∑ot+1∈{L,H} γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O)),
rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C)).
(5.3)
for all pit ∈ [0, 1] and t = 1, . . . , N − 1.
The structural results presented in Section 5.3 and the computational experiments de-
scribed in Section 5.4 provide insight into the value of test accuracy and cost as they relate
to prolonging the life years of a patient. Test accuracy refers not only to the result re-
ceived through testing, but also its ability to inform correct clinical interpretation of the
true underlying health state.
5.3 ANALYZING THE EFFECTS OF TEST COST AND ACCURACY ON
CYTOKINE TESTING AND HOSPITAL DISCHARGE DECISIONS
This section presents structural results for the POMDP model pertaining to changes in test
cost and accuracy. The purpose of this analysis is to provide insight into the robustness of the
model results for a range of model parameters, as can be expected in practice. Experiments
utilizing patient-based data are presented in the following section. Relevant proofs are
provided in the Appendix. First, the following assumptions are made.
67
5.3.1 Additional assumptions for the POMDP model
Assumption 5.3.1 It is assumed that ft(yt, C) = ft(yt, O) = 1 for all yt ∈ Y and for all
t ∈ N .
This assumption states that the immediate reward received for keeping the patient in the
hospital, with or without ordering a cytokine test, is one more day of patient life. Future
research could consider other reward functions, such as incorporating the cost of care.
Assumption 5.3.2 The core patient health transition probability matrix P (t), with entries
[P (t)]yj = pt(j|yt, C) = pt(j|yt, O), is IFR for all t ∈ N .
From definition 4.3.1, this assumption implies that for two patients in health states y and
y+1, respectively, the patient in health state y is more likely to transition to a health state
worse than y in the next stage. In other words, sicker patients are more likely to progress to
being even sicker than are healthier patients.
Assumption 5.3.3 The test has accuracy ρ, i.e., z(L|L) = z(H|H) = ρ.
Through this assumption the model is restricted to consider only symmetric testing accura-
cies.
Assumption 5.3.4 Tests can be inaccurate, i.e., ρ ∈ (1
2
, 1].
This assumption implies that the test results are more likely to be correct than incorrect.
5.3.2 Mathematical analysis of the effects of testing cost and accuracy
With these assumptions, this model is similar to the model presented in Monahan [81],
but applied to a medical decision making application. This model also considers a time-
dependent terminal reward, but this difference does not impact the structural results. The-
orem 5.3.5 restates one of Monahan’s results for the finite-horizon case, which demonstrates
an ordering of the value function over pit for fixed testing cost and test accuracy. As discussed
in Section 2.3.1, a more general result was presented by Smallwood and Sondik [103].
Theorem 5.3.5 [81, 103] For any fixed ρ ∈ (1
2
, 1] and IFR transition probability matrix,
V ∗t (pit) is continuous, nondecreasing, and convex in pit, pit ∈ [0, 1].
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Extending this result, an ordering on the value function with respect to testing cost is
demonstrated in Theorem 5.3.6. Let V ∗t (pit, c) denote the optimal value function value at
stage t when the testing cost is c and the belief variable is pit.
Theorem 5.3.6 V ∗t (pit, c
′) ≤ V ∗t (pit, c′′) for c′ ≥ c′′ and for all t ∈ N .
Proof (By induction) From (5.2) it is known that V ∗N(piN , c
′) = V ∗N(piN , c
′′) = rN(piN). As-
suming that V ∗k (pik, c
′) ≤ V ∗k (pik, c′′) for k = t+1, . . . , N−1, it suffices to show that V ∗t (pit, c′)
≤ V ∗t (pit, c′′) . Following from (3.5), it follows that
V ∗t (pit, c
′) = max

rt(pit, D),
rt(pit, O)− c′ +∑ot+1∈{L,H} γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′),
rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C), c′).
and
V ∗t (pit, c
′′) = max

rt(pit, D),
rt(pit, O)− c′′ +∑ot+1∈{L,H} γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′′),
rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C), c′′).
The induction assumption implies that
V ∗t+1(U(pit+1|ot+1, pit, O), c′′) ≥ V ∗t+1(U(pit+1|ot+1, pit, O), c′) (5.4)
and
V ∗t+1(U(pit+1|∅, pit, C), c′′) ≥ V ∗t+1(U(pit+1|∅, pit, C), c′). (5.5)
Suppose that V ∗t (pit, c
′) = rt(pit, D). By definition, V ∗t (pit, c
′′) ≥ rt(pit, D) = V ∗t (pit, c′).
Next, suppose that
V ∗t (pit, c
′) = rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′).
By definition,
V ∗t (pit, c
′′) ≥ rt(pit, O)− c′′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′′)
≥ rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′′) (5.6)
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≥ rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), c′) (5.7)
= V ∗t (pit, c
′),
where (5.6) follows from the fact that c′ ≥ c′′ and (5.7) follows from the induction assumption
(5.4).
Finally, suppose that V ∗t (pit, c
′) = rt(pit, C)+ γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C), c′). By def-
inition,
V ∗t (pit, c
′′) ≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C), c′′)
≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C), c′) = V ∗t (pit, c′), (5.8)
where (5.8) follows from the induction assumption (5.5) and the desired result follows.
The ordering shown in Theorem 5.3.6 leads to Corollary 5.3.7, which shows that as the
testing cost decreases, the optimal testing region does not decrease.
Corollary 5.3.7 If it is optimal to test in state pit at stage t when the testing cost is c
′, then
it is also optimal to test when the testing cost is c′′ ≤ c′.
Proof Given pit and testing cost c
′, a∗t = O and (3.5) imply that
rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1, O|pit)V ∗t+1(U(pit+1|ot+1, pit, O)) ≥ rt(pit, D)
and that
rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O))
≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C)).
Note that c′′ ≤ c′ implies that
rt(pit, O)− c′′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O))
≥ rt(pit, O)− c′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O)).
Therefore,
rt(pit, O)− c′′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O)) ≥ rt(pit, D)
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and
rt(pit, O)− c′′ +
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O))
≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C)),
and the result follows.
Corollary 5.3.7 demonstrates the intuitive result that when it is optimal to test for a given
test cost c′, then it is also be optimal to test for a lower test cost c′′ given that all other
model parameters remain the same.
Exploring the effects of test accuracy on the optimal value function value, Theorem
5.3.8 restates another result from Monahan [81] for the finite-horizon case. This result
demonstrates an ordering on the value function with respect to test accuracy. Let V ∗t (pit, ρ)
denote the optimal value function value at stage t when the test accuracy is ρ and the belief
variable is pit.
Theorem 5.3.8 [81] V ∗t (pit, ρ
′) ≤ V ∗t (pit, ρ′′) for ρ′ ≤ ρ′′ and for all t ∈ N .
Corollary 5.3.9 expands this result, which shows that as testing accuracy increases, the
optimal testing region does not decrease.
Corollary 5.3.9 If it is optimal to test in state pit at stage t when the test accuracy is ρ
′,
then it is also optimal to test when the test accuracy is ρ′′ ≥ ρ′.
Proof Given pit and test accuracy ρ
′, a∗t = O and (3.5) imply that
rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′) ≥ rt(pit, D)
and that
rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′)
≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit, C)).
Note that following from Theorem 5.3.8, ρ′′ ≥ ρ′ implies that
rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′′)
≥ rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′).
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Therefore,
rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′′) ≥ rt(pit, D)
and
rt(pit, O)− c+
∑
ot+1∈{L,H}
γt(ot+1|pit, O)V ∗t+1(U(pit+1|ot+1, pit, O), ρ′′)
≥ rt(pit, C) + γt(∅|pit, C)V ∗t+1(U(pit+1|∅, pit)),
and the result follows.
Corollary 5.3.9 demonstrates the intuitive result that when it is optimal to test for a given
test accuracy ρ′, then it is also be optimal to test when the test result and/or interpretation
accuracy is improved.
The specific results described in Corollaries 5.3.7 and 5.3.9 are demonstrated through
the computational experiments described in Section 5.4.
5.4 USING PATIENT DATA TO CALIBRATE MODELS OF CYTOKINE
TESTING AND HOSPITAL DISCHARGE DECISIONS
The problem instances described in this section were solved using the modified backward
induction algorithm detailed in Appendix C.
5.4.1 POMDP data sources
The GenIMS trial data contains static and dynamic variables for 2320 patients that were
identified as potentially having community-acquired pneumonia (CAP). Of these patients,
2032 were admitted to the hospital and went on to develop varying degrees of sepsis. The
computational experiments presented in this section utilize a sample of 1096 patients, with
936 patients being excluded from the GenIMS in-patient cohort because they did not have
at least two consecutive days of cytokine test results. Static variables such as age and race
are provided for each patient.
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5.4.2 Interleukin-6
The following computational experiments utilize the cytokine interleukin-6 (IL-6) to repre-
sent the observed value of the patient’s health state. IL-6 has been shown to be a predictor of
severe sepsis and death through studies conducted as part of the GenIMS investigation [63].
In particular, it has been shown that elevated concentrations of this cytokine were higher for
those patients that died following severe sepsis compared to those who survived [63]. Based
on the results of this study, the problem instances tested in this dissertation considered an
IL-6 level of 5.9 pg/mL or less to be low and all levels greater than this value to be high [63].
5.4.3 Problem instances considering various testing costs and accuracy levels
Based on conventions in the literature [22, 23, 24, 50, 62, 63, 65, 96], the values N = 30
days and T = 90 days are used. Since age and race have been determined to be significant
predictors of patient mortality [58, 62], these static variables are used to define problem
instances following the conventions used in [24], [65], and [96]. Due to the sparsity of cytokine
data, problem instances were constructed for the cohort consisting of Caucasian patients age
65 and older. As additional data become available, the model can be used for other age and
race cohorts.
Due to issues with data sparsity when attempting to develop non-stationary probability
matrices, it is assumed that the transition and observation probabilities are stationary;
however, the patient’s (T−t)-day expected survival is calculated as a function of the patient’s
length of stay in the hospital. As additional controlled trials are conducted to study the role
of inflammatory markers in predicting sepsis progression and survival, the availability of
additional data will allow for the consideration of increasingly complex models, such as
those with multiple non-stationary components.
Table 5.1 defines nine problem instances by their observation probabilities and testing
costs. These instances were tested using the general model. As in Section 5.3, symmetric
test accuracies are assumed, i.e., z(L|L) = z(H|H). This dissertation focuses on how testing
accuracy in general affects the optimal policies. Further investigation into changes in test
specificity versus sensitivity is left to future research.
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Table 5.1: Problem Instances Tested Using the POMDP Model
z(L|L) c
A 1 0
B 1 0.5
C 1 1
D 0.95 0
E 0.95 0.5
F 0.95 1
G 0.90 0
H 0.90 0.5
I 0.90 1
5.4.4 Results for various testing costs and accuracy levels
Figure 5.1 displays the optimal discharge and testing policy regions for the nine problem
instances described in Table 5.1. Recall that these problem instances were all solved for
the cohort consisting of Caucasian patients age 65 and older. In Figure 5.1, the problem
instances are presented such that that test accuracy increases from bottom to top and testing
cost increases from left to right. These results are also presented in numerical form in Tables
B1, B2, and B3 in Appendix B.
Three values of test accuracy are considered: 1 (completely accurate), 0.95, and 0.9.
Three values of test cost (in life days) are considered: 0 (no cost), 0.5, and 1. Test cost
is a conversion of dollars to life days using a willingness-to-pay threshold, as done in cost-
effectiveness analysis [48]. For example, 0.5 life days would translate to $685 using a $500,000
per life year willingness-to-pay threshold value or to $1,370 using a $1,000,000 per life year
willingness-to-pay threshold.
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Figure 5.1: Optimal Policy Regions for Each POMDP Problem Instance
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To interpret the optimal policy decision for a patient in a given health state (represented
by the current value of the belief variable) at a particular stage, the clinician would look at
the appropriate problem instance graph and first choose the current stage along the x-axis.
The clinician would next find the current value of the belief variable (i.e., the clinician’s
belief that the patient’s underlying health state is well) along the y-axis and then identify in
which of the three possible action regions these x, y coordinates fall. The lower-most region,
shaded in diagonal lines, represents the Continue region. If the coordinates fall within this
region, then the optimal action is to keep the patient in the hospital for one more day without
ordering a cytokine test. If the coordinates fall within the gray-shaded region, the testing
region, then the optimal action would be to keep the patient in the hospital for one more
day, but to also order a cytokine test. Recall that the test results will be received in the next
stage before a decision is made. Finally, if the coordinates fall in the upper-most region,
shaded white, then the optimal action is to discharge the patient from the hospital without
ordering a cytokine test.
Note that the optimal policy on day 29 is the same for each problem instance. This policy
can be interpreted as: If the belief variable is less than 0.37, keep the patient in the hospital
for one more day and then discharge on day 30; otherwise, discharge the patient from the
hospital on day 29. There is no testing region on day 29 since the model assumes that a
patient that is still in the hospital on day 30 must be discharged from the hospital. A test
result received on day 30 (for a test ordered on day 29) would not change this decision and
is therefore not necessary. Since testing is not involved at the end of the horizon, the nine
problem instances presented are the same on day 29 looking forward and therefore have the
same optimal policy. For the previous stages, however, the varying test costs and accuracies
impact the resulting policies, as can be seen in the differing optimal policies for each problem
instance for days 1 through 28. The convergence of each policy to 0.37 on day 29 can be
described as “end-of-horizon effects.”
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5.4.5 Discussion of POMDP results
To explain further, consider problem instance H, where z(L|L) = 0.9. Suppose that on day
9, the clinician believed that there was a 50% chance that the patient’s IL-6 level was low.
Based on the optimal policy illustrated in Figure 5.1, the clinician would choose to keep the
patient in the hospital for one more day and order a cytokine test. When the test result is
received at the beginning of day 10, the clinician observes the test result and makes another
decision.
Suppose that the test result observed at the beginning of day 10 indicates that the
patient’s IL-6 level is low. With this new information about the patient and with pt(L|L) =
0.81, pt(H|L) = 0.18, pt(L|H) = 0.17, and pt(H|H) = 0.82, the clinician’s new belief variable
value becomes:
U(pit+1|ot+1 = L, pit = 0.5) = z(L|L)[pt(L|L)pit + pt(L|H)(1− pit)]
γt(L|0.5)
=
0.9[0.81 ∗ 0.5 + 0.17 ∗ 0.5]
0.491
= 0.898 ≡ 90%,
where
γt(L|0.5) = z(L|L)[pt(L|L)pit + pt(L|H)(1− pit)] + z(L|H)[pt(H|L)pit + pt(H|H)(1− pit)]
= 0.9[0.81 ∗ 0.5 + 0.17 ∗ 0.5] + 0.1[0.18 ∗ 0.5 + 0.82 ∗ 0.5] = 0.491.
Looking at the chart for instance H, day 10, and belief variable value 0.90, the optimal
decision is to discharge the patient from the hospital.
If, on the other hand, the test results observed at the beginning of day 10 had indicated
that the patient’s IL-6 level was high, then the clinician’s new belief variable value would
have become:
U(pit+1|ot+1 = H, pit = 0.5) = z(H|L)[pt(L|L)pit + pt(L|H)(1− pit)]
γt(H|0.5)
=
0.1[0.81 ∗ 0.5 + 0.17 ∗ 0.5]
0.499
= 0.098 ≡ 10%,
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where
γt(H|0.5) = z(H|L)[pt(L|L)pit + pt(L|H)(1− pit)] + z(H|H)[pt(H|L)pit + pt(H|H)(1− pit)]
= 0.1[0.81 ∗ 0.5 + 0.17 ∗ 0.5] + 0.9[0.18 ∗ 0.5 + 0.82 ∗ 0.5] = 0.499.
Looking at the chart for instanceH, day 10, and belief variable value 0.1, the optimal decision
is to keep the patient in the hospital without ordering a cytokine test. If no cytokine test is
ordered on day 10, then the updated belief variable on day 11 becomes:
U(pi11|∅, 0.098) = pt(L|L)pit + pt(L|H)(1− pit)
= 0.81 ∗ 0.098 + 0.17 ∗ 0.902 = 0.233 ≡ 23%.
Note that the belief variable value increased from 0.1 to 0.23 and that the optimal decision
on day 11 in this state is to order another cytokine test.
These regions can be further explained as follows. For very low values of the belief
variable, the decision maker believes with a high probability that the patient’s cytokine level
is high and it is therefore not necessary to order a test for more information. This additional
information would not change the decision to keep the patient in the hospital, so a test
is not ordered. Similarly, for very high values of the belief variable, the decision maker is
fairly certain that the patient is healthy enough to be discharged from the hospital, and it
is therefore not necessary to order a test for more information. This additional information
would most likely not change the decision to discharge the patient from the hospital, so a
test is not ordered.
Notice that these observations are true even for the case when there is no testing cost and
no test error. The Continue and Discharge regions increase in size as the associated testing
cost increases, confirming the results of Corollary 5.3.7 in Section 5.3. These regions decrease
in size as the associated testing accuracy increases, confirming the results of Corollary 5.3.9
in Section 5.3. The center testing region is highly dependent on both the cost of ordering a
test and the accuracy of the test results. The testing region is largest for Problem Instance
A in which there is no testing cost and the test results are completely accurate. For Problem
Instance I, on the other hand, in which the testing cost is highest and the test accuracy
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is lowest, the testing region is very narrow. The testing region appears to be less affected
when only one parameter, cost or accuracy, is changed, but decreases dramatically as both
become more unfavorable.
5.5 INTERPRETING OPTIMAL POLICIES FOR CLINICAL USE
One drawback of the POMDP model formulation and model output is the difficulty in
translating the results to an applicable strategy. This stems mainly from the use of a belief
variable in the model formulation. The belief variable is updated from one stage to the
next using Bayesian updating, effectively capturing the history of patient health transitions
and observed test results in a single value. Unfortunately, the clinician often considers the
patient’s history explicitly when making a treatment decision. The single belief variable
value alone does not provide enough clinical information to the clinician to be immediately
applicable in practice.
A finite horizon model that considers 30 patient days in the hospital and three possible
test results (low, high, no test) will result in 330 (over 200 trillion) possible combinations
of test results. The belief variable allows for the use of solution techniques that avoid
enumerating each possible solution. The following tables provide some insight into the belief
variable calculation over a short time horizon of four days. In this example, it is assumed
that tests are ordered for four consecutive days and that the first test result is observed
on day 1. Assuming that the test interpretation accuracy is 0.95, Table 5.2 demonstrates
how the belief variable is updated based on all combinations of four consecutive test results,
starting with a low test result on day 1. Table 5.3 demonstrates how the belief variable is
updated based on all combinations of four consecutive test results, starting with a high test
result on day 1.
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These tables demonstrate that a change in the test result received between two consecu-
tive days significantly impacts the belief variable value. For example, even after a 3 low test
results, a single high test result will reduce the belief variable value from 0.9874 to 0.1791.
Similarly, after 3 high test results, a single low test result will raise the belief variable value
from 0.0113 to 0.8039.
Table 5.2: Belief Variable Values (Starting With a Low Test Result on Day 1 and All Possible
Results on Days 2, 3, and 4)
day 1 result day 2 result day 3 result day 4 result
L L L H
0.95 0.9855 0.9874 0.1791
L L H L
0.95 0.9855 0.1780 0.8837
L H L L
0.95 0.1587 0.8772 0.9814
L L H H
0.95 0.9855 0.1780 0.02062
L H L H
0.95 0.1587 0.8772 0.1276
L H H L
0.95 0.1587 0.0194 0.8094
L H H H
0.95 0.1587 0.0194 0.0116
L L L L
0.95 0.9855 0.9874 0.9875
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Table 5.3: Belief Variable Values (Starting With a High Test Result on Day 1 and All
Possible Results on Days 2, 3, and 4)
day 1 result day 2 result day 3 result day 4 result
H L L H
0.05 0.8284 0.9784 0.1738
H L H L
0.05 0.8284 0.1114 0.8588
H H L L
0.05 0.0132 0.8052 0.9768
H L H H
0.05 0.8284 0.1114 0.0166
H H L H
0.05 0.0132 0.8052 0.1046
H H H L
0.05 0.0132 0.0113 0.8039
H H H H
0.05 0.0132 0.0113 0.0112
H L L L
0.05 0.8284 0.9784 0.9870
These values are further put into perspective when compared to the testing and dis-
charge control-limit values presented in Table 5.4. These testing and discharge control limits
correspond to problem instances D, E, and F , which correspond to a test accuracy of 0.95
and test costs, 0, 0.5, and 1, respectively. When comparing the values in Tables 5.2 and 5.3
to Table 5.4, consider, for example, that two low test results in a row in either Table 5.2 or
Table 5.3 will raise the belief variable value above the limit for discharging a patient for all
problem instances. Similarly, even one high test result reduces the belief variable below the
testing limit.
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Table 5.4: POMDP Control Limits (Instances D, E, and F )
day D E F
CL(T ) CL(D) CL(T ) CL(D) CL(T ) CL(D)
1 0.23 0.83 0.26 0.71 0.26 0.57
2 0.23 0.83 0.26 0.71 0.26 0.57
3 0.23 0.83 0.26 0.71 0.26 0.57
4 0.23 0.83 0.26 0.71 0.26 0.57
5 0.23 0.83 0.26 0.71 0.26 0.56
6 0.23 0.83 0.26 0.71 0.27 0.55
7 0.23 0.83 0.26 0.7 0.27 0.55
8 0.23 0.83 0.26 0.7 0.27 0.55
9 0.23 0.83 0.26 0.7 0.27 0.55
10 0.23 0.83 0.26 0.7 0.27 0.54
11 0.23 0.83 0.26 0.7 0.27 0.54
12 0.23 0.83 0.26 0.7 0.29 0.54
13 0.23 0.82 0.26 0.69 0.29 0.53
14 0.23 0.82 0.26 0.69 0.27 0.53
15 0.23 0.82 0.26 0.69 0.29 0.52
16 0.23 0.82 0.26 0.68 0.29 0.52
17 0.23 0.81 0.26 0.68 0.27 0.51
18 0.23 0.81 0.25 0.67 0.29 0.51
19 0.22 0.8 0.26 0.65 0.29 0.5
20 0.22 0.8 0.26 0.65 0.27 0.5
21 0.22 0.79 0.23 0.64 0.3 0.48
22 0.22 0.77 0.26 0.62 0.29 0.47
23 0.22 0.75 0.26 0.61 0.26 0.46
24 0.22 0.73 0.22 0.6 0.3 0.44
25 0.19 0.71 0.26 0.57 0.3 0.44
26 0.22 0.67 0.23 0.54 0.23 0.43
27 0.16 0.62 0.12 0.51 0.29 0.39
28 0.15 0.54 0.29 0.4 0.37 0.37
29 0.37 0.37 0.37 0.37 0.37 0.37
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Once a high test result is received and the belief variable value falls below the testing
limit, then the optimal action is to keep the patient in the hospital for one more stage without
ordering another test. The belief variable value is then updated according to the underlying
core state transition probabilities. Only after the belief variable value has reached the testing
limit, will another test be ordered for that patient. Figure 5.2 displays the testing and
discharge control limits, by stage, for problem instance E, corresponding to a test accuracy
of 0.95 and a test cost of 0.5. This figure also shows how the value of the belief variable is
updated from one day to the next after a high test result on day one and no further test
results. Notice that the belief variable value enters the testing region on day 3. In other
words, if a high test result was received on day 1, then the patient would be kept in the
hospital without testing on days 1 and 2. On day 3, the patient would be kept in the hospital
and another cytokine test would be ordered.
Interpreting this information from a clinical perspective, it is clear that a high test result
is a significant indication that the patient is very sick and should be kept in the hospital.
However, if the patient survives for two days following the high test result, then the patient’s
health has likely improved, and another test result should be ordered.
To generalize this result, Table 5.5 demonstrates how various values of the belief variable
pit are updated from day t to t + 1 after a high test result is received. Notice that pit+1
falls below the test threshold for all t and for all values of pit, as shown in Table 5.5. It can
therefore be concluded, that after a high test result is received, the clinic
Table 5.6 demonstrates how pit is updated from day t to t + 1 when no test result is
received, for the updated belief variable values in Table 5.5. Note that only the largest
values fall above the testing thresholds of the later days in the model, as indicated in Table
5.4.
Finally, Table 5.7 demonstrates the updating of pit+1 from day t+ 1 to day t+ 2 for the
updated values in Table 5.6. These values all fall above the testing thresholds for all values
of pit+1 and all days. Therefore, it is optimal to order another cytokine test when in any of
these belief variable states.
Table 5.8 shows how various values of the belief variable pit would be updated from day t
to t+ 1 when a low test result is received. Notice that all updated belief variable values fall
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Figure 5.2: Belief Variable Value (After a High Test Result on Day 1 and No Further Test
Results)
84
Table 5.5: Updating pit from Day t to t+ 1 After a High Test Result
pit pit+1
0.10 0.02
0.20 0.02
0.30 0.03
0.40 0.04
0.50 0.05
0.60 0.06
0.70 0.08
0.80 0.10
0.90 0.14
Table 5.6: Updating pit from Day t to t+ 1 When No Test Result is Received
pit pit+1
0.02 0.18
0.03 0.19
0.04 0.19
0.05 0.20
0.06 0.21
0.08 0.22
0.10 0.23
0.14 0.25
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Table 5.7: Updating pit+1 from Day t+ 1 to t+ 2 When No Test Result is Received
pit+1 pit+2
0.18 0.28
0.19 0.29
0.20 0.29
0.21 0.30
0.22 0.31
0.23 0.32
0.25 0.33
above the discharge threshold for all days and all values of pit. It can be concluded, therefore,
that a patient should be discharged after a low test result is observed.
Exploring the results for problem instance E has resulted in decision rules that are easy
to implement in practice. If a high test result is observed, wait one to two days, then test
again. If a low test result is observed, discharge the patient.
This approach to interpreting and implementing the POMDP model solutions can be
carried over into an interpretation of a combined SOFA and IL-6 policy based on the POMDP
results discussed in this section and the SOFA results presented for problem instance 2
(Caucasian patients, age 65 years and older) in Chapter 4.
5.5.1 Combined SOFA and IL-6 policy
This section considers an approach for utilizing the SOFA-based MDP model results in ad-
dition to the IL-6-based POMDP model results to inform clinical practice. As additional
data become available, the general model proposed in Section 3 can be used to generate op-
timal results combining completely observable elements (e.g., the SOFA score) and partially
observable elements (e.g., the IL-6 level). In the absence of these data, however, key results
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Table 5.8: Updating pit from Day t to t+ 1 When a Low Test Result is Received
pit pit+1
0.10 0.85
0.20 0.89
0.30 0.92
0.40 0.93
0.50 0.95
0.60 0.96
0.70 0.97
0.80 0.98
0.90 0.98
from Chapters 4 and 5 are combined to form a general strategy for patient care using the
following heuristic approach.
An important consideration when discussing combining the SOFA score and IL-6 infor-
mation is the fact that the SOFA score is directly observable by the clinician and will be
the basis on which most decisions are made in practice. The SOFA score will be considered
before other additional information, such as the patient’s IL-6 level, when making the dis-
charge decision. For example, if a patient has a very high SOFA score, then the patient will
be kept in the hospital, even if the patient’s IL-6 level is low. Therefore, the IL-6 level does
not provide useful information unless the clinician is considering the decision to discharge
the patient from the hospital.
The following heuristic approach to a combined SOFA and IL-6 policy is proposed for
Caucasian patients age 65 and older (corresponding to MDP problem instance 2 and POMDP
problem instance E): Observe the patient’s SOFA score value following the MDP policy as
described in Table A2 in Appendix A. At the point at which the decision is to discharge
the patient, do not discharge the patient, but instead order a cytokine test. If the cytokine
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test result is low in the next stage and the patient’s SOFA score is still within the range to
discharge the patient, then discharge the patient.
If the cytokine test result is high in the next stage, then keep the patient in the hospital
for two more days. If on the second day, the patient’s SOFA score is still in the discharge
range, then order another cytokine test. Again, if the test result is low and the patient’s
SOFA score is still in the discharge range, then discharge the patient. Otherwise wait two
more days, as before, and order another cytokine test. Continue this process until the patient
either dies or is discharged from the hospital.
This policy builds off of current practice with elements of the optimal SOFA and IL-6
policies described in this dissertation. In the IL-6 model, the decision to test rather than
discharge the patient resulted in an average (90−t)-day life expectancy improvement of more
than 4 days, or an average increase of more than 6.7% (for the case of 95% test accuracy
and 0.5 days for test cost). Again, as additional data become available the general model
proposed in Section 3 can be used to measure this improvement for a combined SOFA and
IL-6 model, but it is assumed that similar improvements in patient survival can be expected
from implementing the suggested heuristic policy. Until addition data become available for
more robust modeling, these approaches help to provide structure to the current process and
begin to give insight into the interpretation of complex modeling techniques like POMDPs.
5.6 CONCLUSIONS
The results presented in this chapter demonstrate the need for inexpensive, accurate testing
procedures as well as accurate interpretation of test results. More importantly, however, is
the suggestion that even in light of completely accurate and cost-free tests, it is not optimal
to test all the time. This at first seems to be counterintuitive until one considers that
additional information is only needed if it will change the decision to discharge the patient.
88
Additionally, while this model considers an individual patient’s perspective, one must
also consider the amount of time that the clinician and other health care providers spend in
administering, processing, and analyzing test results. Avoiding unnecessary tests will help
to reduce health care costs from the system perspective.
Using the results of the IL-6-based model together with the SOFA-based policies from
Chapter 4, a heuristic policy is developed utilizing testing as a qualification step for patient
discharge. As additional data become available, the general model proposed in Chapter 3
can be used to develop optimal SOFA- and IL-6-based testing and hospital discharge policies.
Until that time, the general strategies presented in this chapter will help to provide structured
strategies for utilizing new cytokine testing procedures as part of patient treatment.
From this study it is clear that the POMDP framework can be used to solve medical
decision making questions in which aspects of the patient’s health state can only be observed
through a costly or inaccurate testing procedure.
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6.0 CONTRIBUTIONS AND DIRECTIONS FOR FUTURE RESEARCH
6.1 CONTRIBUTIONS TO PATIENT CARE
Expanding upon research to date that has sought to compare various treatment alternatives,
this dissertation is the first study to address the optimization of decisions made in the man-
agement of severe sepsis. In addition, this is the first model of sepsis to consider the question
of cytokine testing, specifically its impact on expected patient survival. The GenIMS trial
is the first study of its kind to provide enough patient data to test the effects of cytokine
testing on patient survival. Using the results of this trial in an optimization model greatly
extends the impacts of this research in the medical community.
In this dissertation, novel models utilizing the MDP and POMDP methodologies that
have only recently been introduced to the medical community are presented. Not only is
the framework of these models shown to be useful for modeling medical decision making
questions in the management of sepsis, but these models are also analyzed mathematically
to uncover clinical conditions that ensure specific types of optimal solutions.
Most importantly, using data from the GenIMS study, these models are then solved for
problem instances constructed from actual patient-based data. The results are interpreted
from a clinical perspective to give recommendations on specific strategies that can be used
to inform clinical practice moving forward.
Finally, the results of both models motivate the need for additional medical research
and demonstrate that, with additional data, these modeling techniques can be used to solve
complex problems that are otherwise too difficult to analyze with common techniques used
by the medical decision making research community today.
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6.2 CONTRIBUTIONS TO STOCHASTIC OPTIMIZATION
The interesting problems found in critical care medicine, such as the management of severe
sepsis, provide the operations research community with unique applications that contribute
to the development of MDP and POMDP theory.
For the MDP model, this dissertation demonstrates clinical conditions for the existence
of control-limit policies using an approach that differs from the standard method described
by Puterman [89]. Computational experiments further illustrate these types of policies for
several problem instances.
For the POMDP models, this dissertation explores the effects of test cost and accuracy on
the optimal testing region and resulting expected patient survival. The results demonstrate
that as testing cost decreases and test accuracy increases, the optimal testing region does not
decrease. In other words, these results give further evidence for the need for less expensive,
more accurate tests. In addition, the results indicate that testing should be used as a
qualification for hospital discharge, but is not necessary if the clinician has already decided
not to discharge the patient based on completely observable factors. For example, even in
the case of no cost, completely accurate tests, it is not always optimal to test. This is because
the additional information from the test result would not change the clinician’s decision to
keep the patient in the hospital and is therefore unnecessary. It is also important to consider
the unquantified savings experienced when not performing unnecessary tests, such as an
improvement in quality of life for the patient and the additional time that the clinician can
spend with the patient, with other patients, or on other activities.
From a research perspective, it is especially beneficial to realize the applicability of
theoretical models in practical applications. It is also helpful to test these models to recognize
their weaknesses and additional opportunities for improvement. While additional data are
needed from the application perspective, the dependence on extremely large quantities of
data from the modeling perspective is also an issue.
The artificial intelligence community is already well underway with exploring methods
by which to capture disease progression by means of influence diagrams and neural networks
so that complete transition probability networks are not needed. Unfortunately, the GenIMS
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study was not far enough along to take advantage of these techniques in this dissertation.
The next section explores several future opportunities for research in this area.
6.3 DIRECTIONS FOR FUTURE RESEARCH
To further validate and gain insights into these models, future research efforts could include
the use of simulation to compare actual strategies to the policies proposed in this dissertation.
For example, Saka et al. [96] presented a simulation model that captured changes in a
patient’s SOFA score over time. The end points in this model were either patient discharge
or death. As a direction for future research, this simulation model could be used to test
the impact of the optimal SOFA-based MDP model results on patient length of stay in the
hospital. These results could then be compared to the actual length of stay in the GenIMS
trial to validate the effectiveness of the model results. Similarly, the model could be updated
to incorporate patient cytokine levels. The updated model could then be used to test the
impact of the optimal IL-6-based POMDP model result on the patient length of stay and
these results could be compared to the actual length of stay. Finally, the average length of
stay resulting from the application of each policy could be compared to assess the value of
the individual models as compared to using the proposed heuristic strategy.
As additional data become available from clinical studies like GenIMS, the models pre-
sented in this dissertation can be used to solve increasingly robust problems involving clinical
decisions in the management of severe sepsis. At the same time, modeling techniques are
being developed to capture the intricate relationships between disease parameters. These
techniques, once refined, will be able to solve, in a reasonable amount of time, increasingly
complex problems in medical decision making.
In addition to these broader directions for research, several immediate applications of
the research from this dissertation are apparent. First, these models can be used to explore
testing and discharge decisions for each cytokine collected in the GenIMS trial, IL-10 and
TNF, for example. This dissertation focused mainly on the application of the model to a
specific example, IL-6, but can also be used to explore these other variables.
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Second, as the interdependencies between the cytokine values are better understood as
a result of the statistical analysis currently being conducted by the GenIMS investigators,
the general POMDP model can be used to consider models with multiple cytokine variables.
This dissertation, due to the data requirements and availability, only considered a single
cytokine variable. However, as more of the statistical relationships are understood, the data
requirements will decrease and become more manageable.
Third, further exploration into the algorithms currently being developed in the artificial
intelligence community may uncover additional ways to solve increasing complex POMDP
models with multiple variables. These methods, combined with the increased understanding
of sepsis resulting from the GenIMS study, will also allow for the development of a more
complex model.
An investigation into conditions for the existence of control-limit policies for both the
MDP and POMDP models would be beneficial. In addition to the investigation of several
structural properties, computational results were mainly used in this dissertation to indicate
that these types of policies exists for these models. However, robust mathematical proofs
would advance the current state of research in these areas. Unfortunately, only very restric-
tive assumptions on the models, too restrictive for this type of application, are necessary.
As was already demonstrated for the MDP model, the restrictive condition did not hold for
the data tested, even though control limit type policies appeared to exist as demonstrated
through the computational results.
Finally, the exploration of other factors that influence clinical decision making, such as
the costs of care, can be incorporated into these models. Currently, the immediate reward
received for keeping a patient in the hospital is a full day of life. Considering factors such
as cost of care would reduce this reward and would likely increase the discharge region for
many if not all problem instances.
It is clear that mathematical modeling techniques such as MDPs and POMDPs are useful
to model questions in the management of sepsis. The investigation of structural properties
and the results demonstrated through computational experiments not only validate the appli-
cability of the modeling techniques, but also serve to provide clinical insight on management
strategies. It is hoped that in the future, as additional data and solution techniques become
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available, that the operations research and medical decision making research communities
will be able to work together to develop clinically robust optimization models that can be
used to inform daily decisions made by clinicians in sepsis management and in other areas
of patient treatment as well.
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APPENDIX A
MDP OPTIMAL SOLUTION OUTPUT
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Table A1: Optimal Solution to MDP Problem Instance 1
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 88.444 89.000 89.000 60.936 D D D C
2 87.370 88.000 88.000 59.567 D D D C
3 86.281 87.000 87.000 57.687 D D D C
4 85.177 86.000 86.000 54.907 C D D C
5 84.016 85.000 85.000 51.148 C D D C
6 82.823 84.000 84.000 44.295 C D D C
7 81.593 83.000 83.000 31.257 D D D C
8 78.720 73.919 60.529 18.376 D C D C
9 77.760 73.022 59.804 18.170 D C D C
10 76.800 72.124 59.077 17.963 D C D C
11 75.840 71.225 58.347 17.756 D C D C
12 74.880 70.325 57.614 17.547 D C D C
13 73.920 69.423 56.877 17.337 D C D C
14 72.960 68.519 56.135 17.125 D C D C
15 72.000 67.612 55.387 16.911 D C D C
16 71.040 66.702 54.630 16.693 D C D C
17 70.080 65.787 53.862 16.471 D C D C
18 69.120 64.865 53.080 16.245 D C D C
19 68.160 63.935 52.282 16.013 D C D C
20 67.200 62.995 51.462 15.773 D C D C
21 66.240 62.039 50.616 15.525 D C D C
22 65.280 61.060 49.739 15.268 D C D C
23 64.320 60.049 48.825 14.999 D C D C
24 63.360 58.986 47.873 14.718 D C D C
25 62.400 57.838 46.889 14.419 D C D C
26 61.440 56.544 45.903 14.081 D C D C
27 60.480 54.986 45.000 13.625 D C D C
28 59.520 52.951 44.286 12.824 D C D C
29 58.560 50.103 43.571 11.186 D C D C
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Table A2: Optimal Solution to MDP Problem Instance 2
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 85.367 83.606 63.617 31.023 D D C C
2 84.408 82.667 61.567 28.743 D D C C
3 83.449 81.727 58.123 25.187 D D C C
4 76.947 72.695 59.095 17.014 D C C C
5 76.053 71.632 57.770 16.271 D C C C
6 75.158 70.561 56.167 14.861 D C C C
7 74.263 69.541 54.269 11.550 D D D C
8 67.739 57.245 45.556 6.415 D D D C
9 66.913 56.547 45.000 6.353 D D D C
10 66.087 55.849 44.444 6.291 D D D C
11 65.261 55.151 43.889 6.229 D D D C
12 64.435 54.453 43.333 6.167 D D D C
13 63.609 53.755 42.778 6.105 D D D C
14 62.783 53.057 42.222 6.043 D D D C
15 61.957 52.358 41.667 5.980 D D D C
16 61.130 51.660 41.111 5.918 D D D C
17 60.304 50.962 40.556 5.856 D D D C
18 59.478 50.264 40.000 5.794 D D D C
19 58.652 49.566 39.444 5.732 D D D C
20 57.826 48.868 38.889 5.670 D D D C
21 57.000 48.170 38.333 5.608 D D D C
22 56.174 47.472 37.778 5.545 D D D C
23 55.348 46.774 37.222 5.483 D D D C
24 54.522 46.075 36.667 5.418 D D D C
25 53.696 45.377 36.111 5.349 D D D C
26 52.870 44.679 35.556 5.261 D D D C
27 52.043 43.981 35.000 5.112 D D D C
28 51.217 43.283 34.444 4.749 D D D C
29 50.391 42.585 33.889 3.648 D D D C
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Table A3: Optimal Solution to MDP Problem Instance 3
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 89.000 89.000 89.000 78.496 D D D C
2 88.000 88.000 88.000 74.406 D D D C
3 87.000 87.000 87.000 69.408 D D D C
4 86.000 82.480 76.807 65.938 D C C C
5 85.000 80.926 74.468 62.215 D C C C
6 84.000 79.265 71.930 58.154 D C C C
7 83.000 77.467 69.167 53.722 D C C C
8 77.176 74.693 66.802 48.699 D C C C
9 76.235 73.742 65.865 47.967 D C C C
10 75.294 72.787 64.910 47.215 D C C C
11 74.353 71.825 63.936 46.439 D C C C
12 73.412 70.857 62.940 45.636 D C C C
13 72.471 69.881 61.920 44.802 D C C C
14 71.529 68.897 60.872 43.933 D C C C
15 70.588 67.904 59.795 43.023 D C C C
16 69.647 66.901 58.684 42.065 D C C C
17 68.706 65.888 57.537 41.050 D C C C
18 67.765 64.866 56.350 39.967 D C C C
19 66.823 63.834 55.122 38.803 D C C C
20 65.882 62.793 53.850 37.537 D C C C
21 64.941 61.746 52.537 36.143 D C C C
22 64.000 60.696 51.185 34.584 D C C C
23 63.059 59.646 49.808 32.805 D C C C
24 62.118 58.596 48.429 30.727 D C C C
25 61.176 57.536 47.095 28.233 D C C C
26 60.235 56.422 45.895 25.142 D C C C
27 59.294 55.123 45.000 21.169 D C C C
28 58.353 53.409 44.286 15.963 D C C C
29 57.412 50.867 43.571 9.095 D C D C
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Table A4: Optimal Solution to MDP Problem Instance 4
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 89.000 82.188 63.846 48.813 D C C C
2 88.000 82.735 65.670 50.940 D C C C
3 87.000 83.469 68.335 54.972 D C C C
4 83.210 86.000 71.667 64.029 C D D C
5 81.901 85.000 70.833 57.175 C D D C
6 80.519 84.000 70.000 45.807 C D D C
7 79.048 83.000 69.167 26.537 D D D C
8 76.875 70.685 56.919 2.000 D C C C
9 75.938 69.827 56.234 2.000 D C C C
10 75.000 68.968 55.546 2.000 D C C C
11 74.063 68.106 54.855 2.000 D C C C
12 73.125 67.242 54.160 2.000 D C C C
13 72.188 66.374 53.460 2.000 D C C C
14 71.250 65.501 52.752 2.000 D C C C
15 70.313 64.621 52.034 2.000 D C C C
16 69.375 63.732 51.302 2.000 D C C C
17 68.438 62.831 50.551 2.000 D C C C
18 67.500 61.912 49.775 2.000 D C C C
19 66.563 60.971 48.965 1.999 D C C C
20 65.625 59.998 48.108 1.998 D C C C
21 64.688 58.983 47.189 1.996 D C C C
22 63.750 57.911 46.185 1.992 D C C C
23 62.813 56.760 45.066 1.984 D C C C
24 61.875 55.504 43.792 1.969 D C C C
25 60.938 54.099 42.312 1.938 D C C C
26 60.000 52.487 40.560 1.875 D C C C
27 59.063 50.568 38.460 1.750 D C C C
28 58.125 48.167 35.945 1.500 D C C C
29 57.188 44.921 33.027 1.000 D C D C
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Table A5: Optimal Solution to MDP Problem Instance 5
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 89.000 89.000 89.000 68.074 D D D C
2 87.857 88.000 88.000 52.147 D D D C
3 86.865 87.000 87.000 51.490 C D D C
4 85.874 86.000 86.000 50.770 C D D C
5 84.884 85.000 85.000 49.932 C D D C
6 83.897 84.000 84.000 48.876 C D D C
7 82.913 83.000 83.000 47.415 C D D C
8 81.934 82.000 82.000 45.201 C D D C
9 80.961 81.000 81.000 41.589 C C D C
10 80.000 80.000 80.000 35.380 C C D C
11 79.000 79.000 79.000 34.951 C C D C
12 78.000 78.000 78.000 34.522 C C D C
13 77.000 77.000 77.000 34.094 C C D C
14 76.000 76.000 76.000 33.665 C C D C
15 75.000 75.000 75.000 33.236 C C D C
16 74.000 74.000 74.000 32.807 C C D C
17 73.000 73.000 73.000 32.378 C C D C
18 72.000 72.000 72.000 31.947 C C D C
19 71.000 71.000 71.000 31.515 C C D C
20 70.000 70.000 70.000 31.077 C C D C
21 69.000 69.000 69.000 30.631 C C D C
22 68.000 68.000 68.000 30.164 C C D C
23 67.000 67.000 67.000 29.656 C C D C
24 66.000 66.000 66.000 29.061 C C D C
25 65.000 65.000 65.000 28.285 C C D C
26 64.000 64.000 64.000 27.128 C C D C
27 63.000 63.000 63.000 25.173 C C D C
28 62.000 62.000 62.000 21.550 C C D C
29 61.000 61.000 61.000 14.433 C C D C
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Table A6: Optimal Solution to MDP Problem Instance 6
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 86.810 89.000 89.000 39.267 D C C C
2 87.447 82.914 70.400 23.894 D C C C
3 86.453 81.972 69.600 23.625 D C C C
4 85.459 81.028 68.800 23.337 D C C C
5 84.465 80.082 68.000 23.002 D C C C
6 83.472 79.133 67.200 22.536 D C C C
7 82.478 78.176 66.400 21.723 D C C C
8 81.484 77.211 65.600 19.980 D C C C
9 80.491 76.235 64.800 15.747 D D D C
10 75.789 60.532 48.000 13.333 D C C C
11 74.842 59.782 47.400 13.167 D C C C
12 73.895 59.033 46.800 13.000 D C C C
13 72.947 58.283 46.200 12.833 D C C C
14 72.000 57.533 45.600 12.667 D C C C
15 71.053 56.784 45.000 12.500 D C C C
16 70.105 56.034 44.400 12.333 D C C C
17 69.158 55.284 43.800 12.167 D C C C
18 68.210 54.534 43.200 12.000 D C C C
19 67.263 53.784 42.600 11.833 D C C C
20 66.316 53.034 42.000 11.667 D C C C
21 65.368 52.283 41.400 11.500 D C C C
22 64.421 51.532 40.800 11.333 D C C C
23 63.474 50.778 40.200 11.167 D C C C
24 62.526 50.022 39.600 11.000 D C C C
25 61.579 49.259 39.000 10.833 D C C C
26 60.632 48.487 38.400 10.667 D C C C
27 59.684 47.697 37.800 10.500 D C C C
28 58.737 46.873 37.200 10.333 D C C C
29 57.789 45.990 36.600 10.167 D C C C
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Table A7: Optimal Solution to MDP Problem Instance 7
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 82.154 79.876 69.406 31.069 C D C C
2 79.666 79.810 66.449 20.423 D D C C
3 78.760 78.897 65.694 19.739 D C D C
4 77.855 77.968 64.939 18.828 D C D C
5 76.950 77.001 64.184 17.582 D C D C
6 76.045 75.925 63.429 15.839 D C D C
7 75.139 74.554 62.673 13.358 D C D C
8 74.234 72.380 61.918 9.783 D C D C
9 73.329 68.015 61.163 4.586 D D D C
10 64.167 51.765 31.304 1.000 D D C C
11 63.365 51.118 30.913 1.000 D D C C
12 62.562 50.471 30.522 1.000 D D C C
13 61.760 49.824 30.130 1.000 D D C C
14 60.958 49.176 29.739 1.000 D D C C
15 60.156 48.529 29.348 1.000 D D C C
16 59.354 47.882 28.956 1.000 D D C C
17 58.552 47.235 28.565 1.000 D D C C
18 57.750 46.588 28.174 1.000 D D C C
19 56.948 45.941 27.783 1.000 D D C C
20 56.146 45.294 27.391 1.000 D D C C
21 55.344 44.647 27.000 1.000 D D C C
22 54.542 44.000 26.609 1.000 D D C C
23 53.740 43.353 26.217 1.000 D D C C
24 52.937 42.706 25.826 1.000 D D C C
25 52.135 42.059 25.435 1.000 D D C C
26 51.333 41.412 25.043 1.000 D D C C
27 50.531 40.765 24.652 1.000 D D C C
28 49.729 40.118 24.261 1.000 D D C C
29 48.927 39.471 23.870 1.000 D D C C
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Table A8: Optimal Solution to MDP Problem Instance 8
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 89.000 89.000 89.000 62.943 D D D C
2 88.000 88.000 88.000 61.823 D D D C
3 87.000 87.000 87.000 60.423 D D D C
4 86.000 86.000 86.000 58.551 C C D C
5 85.000 85.000 85.000 56.605 C C D C
6 84.000 84.000 84.000 53.317 C C D C
7 83.000 83.000 83.000 47.256 C C D C
8 82.000 82.000 82.000 35.461 C C D C
9 81.000 81.000 81.000 35.043 C C D C
10 80.000 80.000 80.000 34.624 C C D C
11 79.000 79.000 79.000 34.206 C C D C
12 78.000 78.000 78.000 33.787 C C D C
13 77.000 77.000 77.000 33.368 C C D C
14 76.000 76.000 76.000 32.949 C C D C
15 75.000 75.000 75.000 32.531 C C D C
16 74.000 74.000 74.000 32.111 C C D C
17 73.000 73.000 73.000 31.692 C C D C
18 72.000 72.000 72.000 31.271 C C D C
19 71.000 71.000 71.000 30.847 C C D C
20 70.000 70.000 70.000 30.418 C C D C
21 69.000 69.000 69.000 29.978 C C D C
22 68.000 68.000 68.000 29.516 C C D C
23 67.000 67.000 67.000 29.009 C C D C
24 66.000 66.000 66.000 28.409 C C D C
25 65.000 65.000 65.000 27.618 C C D C
26 64.000 64.000 64.000 26.436 C C D C
27 63.000 63.000 63.000 24.455 C C D C
28 62.000 62.000 62.000 20.835 C C D C
29 61.000 61.000 61.000 13.857 D D D C
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Table A9: Optimal Solution to MDP Problem Instance 9
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 87.749 89.000 89.000 42.929 D D D C
2 86.738 88.000 88.000 39.206 D D D C
3 85.721 87.000 87.000 31.115 D D D C
4 85.196 83.795 68.800 21.923 D D C C
5 84.206 82.821 68.000 21.146 D D C C
6 83.215 81.846 67.200 19.466 D D C C
7 82.224 80.872 66.400 15.361 D D D C
8 79.311 63.490 47.953 13.667 D C C C
9 78.344 62.726 47.386 13.500 D C C C
10 77.377 61.962 46.818 13.333 D C C C
11 76.410 61.198 46.250 13.167 D C C C
12 75.443 60.434 45.681 13.000 D C C C
13 74.475 59.668 45.111 12.833 D C C C
14 73.508 58.902 44.540 12.667 D C C C
15 72.541 58.134 43.966 12.500 D C C C
16 71.574 57.364 43.389 12.333 D C C C
17 70.607 56.591 42.809 12.167 D C C C
18 69.639 55.815 42.223 12.000 D C C C
19 68.672 55.034 41.631 11.833 D C C C
20 67.705 54.245 41.028 11.667 D C C C
21 66.738 53.447 40.413 11.500 D C C C
22 65.770 52.636 39.781 11.333 D C C C
23 64.803 51.805 39.125 11.167 D C C C
24 63.836 50.945 38.442 11.000 D C C C
25 62.869 50.041 37.724 10.833 D C C C
26 61.902 49.066 36.970 10.667 D C C C
27 60.934 47.969 36.193 10.500 D C C C
28 59.967 46.648 35.443 10.333 D C C C
29 59.000 44.891 34.857 10.167 D C C C
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Table A10: Optimal Solution to MDP Problem Instance 10
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 88.321 89.000 89.000 43.525 D D D C
2 87.328 88.000 88.000 40.571 D D D C
3 86.336 87.000 87.000 34.288 D D D C
4 84.925 84.346 78.182 24.441 D D C C
5 83.938 83.365 77.273 23.517 D D C C
6 82.950 82.385 76.364 21.496 D D C C
7 81.963 81.404 75.455 16.524 D D D C
8 79.897 67.368 61.500 10.250 D C C C
9 78.923 66.551 60.750 10.125 D C C C
10 77.949 65.735 60.000 10.000 D C C C
11 76.974 64.918 59.250 9.875 D C C C
12 76.000 64.102 58.500 9.750 D C C C
13 75.026 63.285 57.750 9.625 D C C C
14 74.051 62.469 57.000 9.500 D C C C
15 73.077 61.652 56.250 9.375 D C C C
16 72.103 60.835 55.500 9.250 D C C C
17 71.128 60.018 54.750 9.125 D C C C
18 70.154 59.201 54.000 9.000 D C C C
19 69.179 58.382 53.250 8.875 D C C C
20 68.205 57.563 52.500 8.750 D C C C
21 67.231 56.740 51.750 8.625 D C C C
22 66.256 55.913 51.000 8.500 D C C C
23 65.282 55.078 50.250 8.375 D C C C
24 64.308 54.229 49.500 8.250 D C C C
25 63.333 53.353 48.750 8.125 D C C C
26 62.359 52.431 48.000 8.000 D C C C
27 61.385 51.426 47.250 7.875 D C D C
28 60.410 50.271 46.500 7.750 D C D C
29 59.436 48.851 45.750 7.625 D C D C
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Table A11: Optimal Solution to MDP Problem Instance 11
t V ∗t (h) A∗t (h)
h = 1 h = 2 h = 3 h = 4 h = 1 h = 2 h = 3 h = 4
1 85.764 81.472 69.388 44.093 D D C C
2 84.800 79.617 66.126 36.006 D D C C
3 83.836 77.333 62.826 26.446 D D C C
4 77.502 76.750 59.939 14.833 D C C C
5 76.601 75.470 59.242 12.595 D C D C
6 75.700 73.598 58.545 9.542 D C D C
7 74.798 70.231 57.849 5.348 D D D C
8 68.163 56.871 44.514 1.000 D D D C
9 67.331 56.177 43.971 1.000 D D D C
10 66.500 55.484 43.429 1.000 D D D C
11 65.669 54.790 42.886 1.000 D D D C
12 64.838 54.097 42.343 1.000 D D D C
13 64.006 53.403 41.800 1.000 D D D C
14 63.175 52.710 41.257 1.000 D D D C
15 62.344 52.016 40.714 1.000 D D D C
16 61.513 51.323 40.171 1.000 D D D C
17 60.681 50.629 39.629 1.000 D D D C
18 59.850 49.935 39.086 1.000 D D D C
19 59.019 49.242 38.543 1.000 D D D C
20 58.188 48.548 38.000 1.000 D D D C
21 57.356 47.855 37.457 1.000 D D D C
22 56.525 47.161 36.914 1.000 D D D C
23 55.694 46.468 36.371 1.000 D D D C
24 54.863 45.774 35.829 1.000 D D D C
25 54.031 45.081 35.286 1.000 D D D C
26 53.200 44.387 34.743 1.000 D D D C
27 52.369 43.694 34.200 1.000 D D D C
28 51.538 43.000 33.657 1.000 D D D C
29 50.706 42.306 33.114 1.000 D D D C
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Table B1: Optimal Solution to POMDP Problem Instances A,B, and C
t A B C
CL(T ) CL(D) CL(T ) CL(D) CL(T ) CL(D)
1 0.21 0.89 0.23 0.79 0.26 0.66
2 0.21 0.89 0.23 0.79 0.26 0.66
3 0.21 0.89 0.23 0.79 0.26 0.66
4 0.21 0.89 0.23 0.78 0.26 0.65
5 0.21 0.89 0.23 0.78 0.26 0.65
6 0.21 0.89 0.23 0.78 0.26 0.65
7 0.21 0.89 0.23 0.78 0.26 0.64
8 0.21 0.89 0.23 0.78 0.26 0.64
9 0.21 0.89 0.23 0.78 0.26 0.64
10 0.21 0.89 0.24 0.77 0.26 0.63
11 0.21 0.89 0.23 0.77 0.26 0.63
12 0.21 0.88 0.23 0.77 0.26 0.62
13 0.21 0.88 0.24 0.76 0.26 0.62
14 0.21 0.88 0.23 0.76 0.26 0.62
15 0.21 0.88 0.23 0.76 0.27 0.61
16 0.21 0.87 0.24 0.75 0.27 0.6
17 0.2 0.87 0.23 0.75 0.26 0.6
18 0.21 0.86 0.23 0.74 0.28 0.59
19 0.2 0.86 0.24 0.73 0.27 0.58
20 0.19 0.85 0.23 0.72 0.26 0.57
21 0.2 0.84 0.21 0.71 0.26 0.56
22 0.18 0.83 0.24 0.69 0.28 0.55
23 0.18 0.81 0.23 0.68 0.23 0.54
24 0.18 0.79 0.2 0.66 0.27 0.51
25 0.15 0.76 0.24 0.62 0.29 0.49
26 0.18 0.72 0.22 0.6 0.22 0.48
27 0.12 0.67 0.12 0.55 0.24 0.43
28 0.12 0.58 0.26 0.44 0.37 0.37
29 0.37 0.37 0.37 0.37 0.37 0.37
108
Table B2: Optimal Solution to POMDP Problem Instances D,E, and F
t D E F
CL(T ) CL(D) CL(T ) CL(D) CL(T ) CL(D)
1 0.23 0.83 0.26 0.71 0.26 0.57
2 0.23 0.83 0.26 0.71 0.26 0.57
3 0.23 0.83 0.26 0.71 0.26 0.57
4 0.23 0.83 0.26 0.71 0.26 0.57
5 0.23 0.83 0.26 0.71 0.26 0.56
6 0.23 0.83 0.26 0.71 0.27 0.55
7 0.23 0.83 0.26 0.7 0.27 0.55
8 0.23 0.83 0.26 0.7 0.27 0.55
9 0.23 0.83 0.26 0.7 0.27 0.55
10 0.23 0.83 0.26 0.7 0.27 0.54
11 0.23 0.83 0.26 0.7 0.27 0.54
12 0.23 0.83 0.26 0.7 0.29 0.54
13 0.23 0.82 0.26 0.69 0.29 0.53
14 0.23 0.82 0.26 0.69 0.27 0.53
15 0.23 0.82 0.26 0.69 0.29 0.52
16 0.23 0.82 0.26 0.68 0.29 0.52
17 0.23 0.81 0.26 0.68 0.27 0.51
18 0.23 0.81 0.25 0.67 0.29 0.51
19 0.22 0.8 0.26 0.65 0.29 0.5
20 0.22 0.8 0.26 0.65 0.27 0.5
21 0.22 0.79 0.23 0.64 0.3 0.48
22 0.22 0.77 0.26 0.62 0.29 0.47
23 0.22 0.75 0.26 0.61 0.26 0.46
24 0.22 0.73 0.22 0.6 0.3 0.44
25 0.19 0.71 0.26 0.57 0.3 0.44
26 0.22 0.67 0.23 0.54 0.23 0.43
27 0.16 0.62 0.12 0.51 0.29 0.39
28 0.15 0.54 0.29 0.4 0.37 0.37
29 0.37 0.37 0.37 0.37 0.37 0.37
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Table B3: Optimal Solution to POMDP Problem Instances G,H, and I
t G H I
CL(T ) CL(D) CL(T ) CL(D) CL(T ) CL(D)
1 0.25 0.76 0.26 0.63 0.27 0.48
2 0.25 0.76 0.26 0.63 0.27 0.47
3 0.25 0.77 0.26 0.63 0.27 0.47
4 0.25 0.77 0.26 0.62 0.27 0.47
5 0.25 0.77 0.26 0.62 0.27 0.47
6 0.25 0.77 0.26 0.62 0.29 0.47
7 0.25 0.77 0.26 0.62 0.29 0.46
8 0.25 0.77 0.26 0.62 0.29 0.46
9 0.25 0.77 0.26 0.62 0.29 0.46
10 0.25 0.77 0.27 0.62 0.29 0.46
11 0.25 0.77 0.26 0.62 0.29 0.45
12 0.25 0.76 0.26 0.61 0.29 0.44
13 0.25 0.76 0.27 0.61 0.29 0.44
14 0.23 0.76 0.26 0.61 0.29 0.44
15 0.25 0.75 0.26 0.61 0.3 0.43
16 0.23 0.75 0.27 0.6 0.3 0.43
17 0.23 0.75 0.26 0.6 0.3 0.43
18 0.25 0.75 0.26 0.6 0.3 0.43
19 0.23 0.74 0.27 0.59 0.3 0.42
20 0.23 0.74 0.26 0.59 0.3 0.41
21 0.23 0.73 0.26 0.57 0.3 0.41
22 0.23 0.72 0.27 0.56 0.3 0.41
23 0.23 0.71 0.26 0.55 0.3 0.4
24 0.23 0.68 0.23 0.53 0.3 0.4
25 0.21 0.66 0.22 0.51 0.3 0.39
26 0.23 0.62 0.23 0.5 0.28 0.39
27 0.15 0.58 0.2 0.47 0.37 0.37
28 0.19 0.51 0.32 0.37 0.37 0.37
29 0.37 0.37 0.37 0.37 0.37 0.37
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APPENDIX C
ALGORITHMS
C.1 BACKWARD INDUCTION ALGORITHM
1. Set t = N and V ∗t (h) = rN(hN) for all hN ∈ H.
2. Substitute t− 1 for t. For all ht ∈ H, perform steps a and b. Then go to step 3.
a. Set
V ∗t (ht) = max
 rt(ht, D),rt(ht, C) +∑H+1j=1 pt(j|ht, C)Vt+1(j).
b. Set
A∗t (ht) = arg max
 rt(ht, D),rt(ht, C) +∑H+1j=1 pt(j|ht, C)Vt+1(j).
3. If t = 1, stop; otherwise return to step 2.
The reader is referred to Puterman [89] for more information.
C.2 MODIFIED BACKWARD INDUCTION ALGORITHM
Discretize the possible belief variable values according to a specified precision, such as 0.01.
Let Π denote the set of all possible values of pit for all t ∈ N .
1. Set t = N and
V ∗t (pit) = rN(piN) for all piN ∈ Π.
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2. Substitute t− 1 for t. For all pit ∈ Π, perform steps a and b. Then go to step 3.
a. Calculate γt(ot+1|pit) for all ot+1 ∈ {H,L} given the current value of pit.
b. Calculate U(pit+1|ot+1, pit) = pit+1 for all ot+1 ∈ {H,L, ∅} given the current value of
pit. Round the calculated value of pit+1 to the closest value contained in Π.
3. For all pit ∈ Π, perform steps a and b. Then go to step 4.
a. Set
V ∗t (pit) = max

rt(pit, D),
rt(pit, O)− c+∑ot+1∈{L,H} γt(ot+1|pit)V ∗t+1(U(pit+1|ot+1, pit)),
rt(pit, C)V
∗
t+1(U(pit+1|∅, pit)).
b. Set
A∗t (pit) = arg max

rt(pit, D),
rt(pit, O)− c+∑ot+1∈{L,H} γt(ot+1|pit)V ∗t+1(U(pit+1|ot+1, pit)),
rt(pit, C) + γt(∅|pit, at)V ∗t+1(U(pit+1|∅, pit)).
4. If t = 1, stop; otherwise return to step 2.
The reader is referred to Monahan [82] for more information.
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